Preprint, Ver. 4 (Aug 3, 2020) - *the manuscript has not been peer-reviewed yet.*

Title: Estimating COVID-19 under-reporting across 86 nations: implications for projections and control

Authors: Hazhir Rahmandad[1*], Tse Yang Lim[1], John Sterman[1]

Affiliations:

[1]Massachusetts Institute of Technology, Cambridge, MA

*Correspondence to: hazhir@mit.edu

Abstract: COVID-19 prevalence and mortality remain uncertain. For all 86 countries with reliable testing data we estimate how asymptomatic transmission, disease acuity, hospitalization, and behavioral responses to risk shape pandemic dynamics. Estimated cumulative cases and deaths through 10 July 2020 are 10.5 and 1.47 times official reports, yielding an infection fatality rate (IFR) of 0.65%, with wide variation across nations. Despite underestimation, herd immunity remains distant. Sufficient early testing could have averted 39.7 (35.3-45.3) million cases and 218 (191-257) thousand deaths. Responses to perceived risk cause the reproduction number to settle near 1, but with very different steady-state incidence, while some nations experience endogenous rebounds. Scenarios through March 2021 show modest enhancements in responsiveness could reduce cumulative cases ≈80%, to 271 (254-412) million across these nations.

One Sentence Summary: COVID-19 under-reporting is large, varies widely across nations, and strongly conditions projected outbreak dynamics.

Main Text: Effective responses to the COVID-19 pandemic require an understanding of its global magnitude and risks. Yet more than four months after WHO declared a global pandemic, the true number of cases and infection fatality rate remain uncertain and the experience of different nations varies widely. As of mid-July, 2020, countries have reported cumulative cases ranging between 4.61 and 3580 per 100,000, and case fatality rates between 0.1% and 15.7%. Asymptomatic infection (*1*), variation in testing rates across countries (*2*), and false negatives (*3-5*) complicate assessment of the true magnitude of the pandemic from official data. The inference problem also requires disentangling other explanatory mechanisms: (i) differences in population density and social networks create variations in the effective reproduction number, R_E; (ii) risk perceptions, behavioral change and policy responses alter transmission rates endogenously; (iii) weather may play a role in transmission (*6*); (iv) testing is prioritized based on symptoms and risk factors, so detection depends on both testing rates and current prevalence (*7*); (v) limited hospital capacity is allocated based on case severity, influencing

fatality rates; (vi) age, socio-economic status, and comorbidities affect severity (*8, 9*); and (vii) all these vary across nations.

Prior studies have shed light on important parts of the puzzle by estimating basic epidemiological parameters and IFR in well-controlled settings (*10*), assessing the asymptomatic fraction and prevalence in specific populations (*11-16*), estimating the role of undocumented infections (*15, 17*), illuminating the effects of various interventions on expected future cases (*18-24*), and contrasting risks and healthcare demands across countries and populations (*23, 25-27*). Yet we lack a global view of the pandemic that is simultaneously consistent with these more focused findings, explains variation in official case and death counts across countries spanning three orders of magnitude, and offers projections accounting for endogenous behavioral responses underpinning second waves (*28*) and long-term incidence.

Model, estimation, and validation

We use a multi-country modified SEIR model to simultaneously estimate SARS-CoV-2 transmission across 86 countries. For each country the model tracks the population from susceptible through pre-symptomatic, infected, and recovered or deceased states, with explicit states for those whose cases are detected or undetected, and hospitalized or not (Figure 1).

<Figure 1 Here>

Besides its multi-nation scope, the model includes three novel features. First, testing capacity is allocated to individuals based on symptom severity relative to available capacity for each. We model symptom severity with a zero-inflated Poisson distribution, where zero severity indicates asymptomatic infection (S1 and Figure S3 provide details). Individuals with more severe symptoms (including those with COVID-19 and those without but with similar symptoms or risk factors, e.g. healthcare workers) get priority for testing. Prioritized test allocation determines the ascertainment rate of COVID-positive cases as a function of the current testing rate and prevalence. It also results in different average COVID severity in the tested vs. untested populations (*29*). We also account for false negatives from RT-PCR COVID tests (*3, 4*). Second, hospital capacity is allocated between COVID-positive cases and demand from non-COVID patients. Mortality (IFR) therefore depends endogenously on the adequacy of hospital capacity relative to the burden of severe cases, along with the age distribution of the population (*8, 9*).

Third, the hazard rate of transmission responds to the perceived risk of COVID. Perceived risk reduces transmission through non-pharmaceutical interventions (NPIs), from social distancing and masking to stay-at-home and business shut-down orders. Perceived risk is based on subjective perceptions of the hazard of infection and death, which respond with a lag to both official data (reported in the media) and actual symptomatic prevalence (gleaned from personal experience and word of mouth). Rising infection rates and mortality increase perceived risk, with a lag, driving the hazard rate of transmission down, while declining cases and deaths can lead to the erosion of perceived risk and adherence to NPIs, leading to the potential for rebound outbreaks.

Model parameters are specified based on prior literature and formal estimation. Parameters specified from the literature include the incubation period (5 days (*8, 30*)), onset-to-detection delay (5 days (*30*)),

post-onset illness duration (15 days (*8*)), and the sensitivity of RT-PCR-based testing (70% (*3, 4*)). Sensitivity analysis is presented in S7.

We estimate the remaining parameters using a panel of data covering all nations with at least 1000 confirmed COVID-19 cases by 10 July 2020 and sufficient testing data to enable parameter estimation, a total of 86 nations spanning 4.76 billion people. These include all disease hotspots to date with two notable exceptions, China and Brazil, for which reliable testing data are not available. The panel includes reported daily testing rates, reported COVID+ cases and deaths, all-cause mortality (where available); along with population, population density, age distribution, hospital capacity, and daily meteorological data. Estimation is by maximum likelihood, using a negative binomial likelihood function. To avoid overfitting, we do not use any time-varying parameters in the estimation. We also use a hierarchical Bayesian framework (*31*) to estimate country-level heterogeneity in each model parameter using informed priors on cross-country parameter variances (see S7 for sensitivity analysis on priors). For example, the asymptomatic fraction of cases and other parameters representing biological processes should have low cross-national variance, whereas parameters specifying risk perceptions and responses are expected to vary more widely. These choices reduce the quality of fit for some nations compared to estimates that allow the parameters for each nation to be independent, but enhance the generalizability of parameter estimates and the robustness of projections. Uncertainties are quantified using a Markov Chain Monte Carlo method designed for high dimensional parameter spaces (*32*) (details in S2).

We validated the estimation framework using synthetic data, generated by simulating the model with known parameters and adding auto-correlated random noise in infection rates and IFR. Our estimation procedure accurately identifies the vast majority of parameters in the synthetic dataset. The absolute error between the estimated and true values was significantly smaller than the estimated uncertainty (median error 13% of the 95% credible interval (CI), with 83% of the absolute errors less than half the 95%CI; see S3 for details).

Figure 2 compares actual and simulated reported daily new cases and deaths for 24 larger countries; S5 reports the full sample. Over the full set of nations, Mean Absolute Errors Normalized by mean (MAEN) are 4.0% and 8.1% for cumulative infections and deaths, respectively, and less than 20% for 68 (79.1%) and 67 (77.9%) of the 86 nations, despite wide variation in the size and dynamics of national outbreaks, from those nearly quenched (France, Germany), to those still growing (India, Mexico) to those exhibiting second waves (Iran, USA). R^2 exceeds 0.9 for 57% of 344 country-specific time series and 0.5 for 84%. Aggregation of within-nation heterogeneities reduces the quality of fit in a few countries. For example, we do not explicitly capture inter-state variation (a contributor to the larger-than-estimated second wave in the USA), or outbreaks concentrated among subpopulations such as migrant workers (Qatar, Singapore) and nursing homes (Belgium, France). The coupling of parameters across countries also limits fits for outliers.

<Figure 2 Here>

Quantifying under-reporting and IFR

We find COVID-19 prevalence and deaths are widely under-reported. Across the 86 nations, the estimated ratio of actual to reported cumulative cases (through 10 July 2020) is 10.5, corresponding to 108 million undetected cases (95% CI 101-113 million). Underreporting varies substantially across nations (10th-90th percentile range 3.35-23.81; Figure 3A).

Underreporting is due in part to the large fraction of asymptomatic infections, estimated at 55%, consistent with many other estimates (*33*). The mean inter-quartile range, MIQR, of the credible intervals in the national estimates is 3.7%. However, the estimated asymptomatic fraction varies little across nations (standard deviation, σ=1.5%) and therefore cannot explain the large cross-national variation in the ratio of estimated to reported cases (Figure 3A).

The extent of underestimation depends primarily on testing capacity and how it is utilized. If every person could be tested the estimated ratio of actual to reported cases would be approximately 1.43, given assumed test sensitivity of ≈70% *(4, 5)*. Testing capacity is limited, however, and so testing prioritizes individuals based on symptom severity. When testing rates are low relative to prevalence, a large proportion of those tested will be positive, but many infected individuals will go undetected, increasing the degree of underestimation (e.g. Mexico). Conversely, when testing capacity is high relative to prevalence (e.g., New Zealand), more of those infected will be identified.

COVID-19 deaths are also underreported (Figure 3A). Across the 86 countries we estimate 700 (674-719) thousand deaths by 10 July 2020, 1.47 times larger than reported, with large cross-national variance (10th-90th percentile range 0.73-3.01). Results are consistent with some other country-specific estimates (*34, 35*) and show an overall declining trend due to increasing test rates. Death undercounts are significantly lower than cases: deaths are concentrated among severe cases who are more likely to have been tested, while post-mortem testing corrects some of the undercount.

National IFR estimates are reported in Figure 3B. Simulated IFR varies endogenously over time based on the adequacy of treatment capacity. IFR in the 86 nations through 10 July 2020 is 0.65% (CI: 0.63%-0.68%), with wide cross-national variation, from 0.13% (CI: 0.12%-0.16%; Qatar) to 2.01% (CI: 1.74%-2.22%; Italy), a range similar to estimates across the USA (*36*). In the model, these variations arise from differences in age distribution (*9*) and the adequacy of health care. Consistent with prior estimates (*23*), we find that hospitalization can reduce the age- and severity-adjusted risk of death to 37% of the rate without treatment, but with large cross-national variation (σ=18%; MIQR: 7.6%).

<Figure 3 Here>

We also find significant heterogeneity across countries in the initial effective reproduction number, R_E (median 3.90, IQR 2.86-5.47), reflecting differences in population density, social networks, and cultural practices (Figure S8 provides details). Importantly, R_E falls over time as people and policymakers respond to perceived risk (*37*). We find behavioral and policy responses to changes in infection risk were adopted rapidly, reducing transmission and R_E with a mean lag of 10 days, though with substantial cross-national variation (σ=6.8; MIQR: 3.5). Those responses are relaxed as perceived risk falls, though more slowly (mean lag 90 days; σ=31; MIQR: 49). Relaxation of the risk response endogenously generates rebounds observed to date in a few nations (e.g., Iran, Australia, Switzerland).

However, such rebounds in the data thus far are rare, yielding large CIs for the risk erosion parameters, creating uncertainty in projections.

Testing shapes early trajectories

Risk perception, individual behavior and government policy, testing, and treatment change through several important feedbacks. We find that those with a positive test reduce their infectious contacts substantially (Mean: 14% of original contact rate; σ=4.9%; MIQR: 11%). These reductions are especially important because symptomatic individuals, who are more likely to get tested, are estimated to be more infectious than asymptomatic ones (Mean asymptomatic infectiousness vs. symptomatic: 28.3%; σ=0.55%; MIQR: 2.5%; consistent with (*15*)).

Crucially, testing also regulates the reported rate of infection, which drives perceived risk. More reported cases increases perceived risk, triggering behavioral and policy responses essential that reduce transmission. The interaction of testing and transmission creates a self-reinforcing bifurcation in the early stages of the epidemic (Figure 4). Plentiful early testing results in high detection rates, greater perceived risk, and stronger responses, slowing transmission. South Korea, for instance, rapidly expanded testing early on (moving left-to-right in Figure 4), identifying more infections, which helped limit transmission (moving top-to-bottom). Conversely, insufficient early testing increases underestimation, limiting perceived risk and allowing transmission to further outpace testing (see Mexico's trajectory in Figure 4). Testing thus reduces new cases, allowing a larger fraction of severe cases to be hospitalized, reducing IFR. The exponential nature of contagion means even small early differences can lead to large differences in epidemic size (*38*), and thus IFR.

<Figure 4 Here>

Figure 5 shows the impact of these feedbacks by comparing the estimated results to a counterfactual in which all countries increase testing to 0.1% of their population per day, a rate currently achieved by multiple countries. We assume enhanced testing begins when WHO declared COVID-19 a pandemic (11 March 2020). We find enhanced testing would have reduced total cases from 108 million to 68.3 (CI: 63.9-73.9) million, with a reduction in deaths from 700K to 482K (CI: 455K-521K).

<Figure 5 Here>

Projections with endogenous responses to risk

We explore three scenarios projecting the pandemic through 20 March 2021, all excluding vaccines and new treatments (Figure 6): (I) Baseline: assumes country-specific testing rates continue as of 10 July 2020; (II) High Testing: 0.1% of the population is tested per day, beginning 16 July 2020; and (III) Responsive: testing remains at current levels, but responses to perceived risk increase (S5). Scenario III represents a modest reduction in transmission for given levels of perceived risk: on average, contact rates fall by 13% (σ=20%) on the day of adoption, comparable to the impact of masks and physical distancing (*39*).

Figure 6A contrasts the results. Scenario I yields 1.48 billion cumulative cases by 20 March 2021, with most cases concentrated in a few countries, including India (885 million median cumulative cases; 95% CI 831-933 million), Pakistan (115 million; 100-128), Bangladesh (51 million; 40-63), and the USA (47 million; 41-53); Figure 6B and C show estimated actual cases and deaths (cumulative and daily; Supplement S5 provides Scenario I projections for all countries). Scenario II reduces cumulative cases 12%, to 1.30 billion. The improvement is modest compared to the large impact of enhanced testing early in the pandemic (Figure 5) because reported cases and deaths have already risen enough by July 2020 that risk perception is not the bottleneck to action. In contrast, Scenario III reduces cumulative cases (Figure 6A) by 82%, to 271 million (CI: 254-412). The largest improvements arise in countries currently estimated to have insufficient responses to control the epidemic (Figure 6D), including India, Pakistan and Bangladesh.

Across scenarios, a few nations continue to experience significant outbreaks, but most are able to stabilize their epidemics following a peak and decline in infection rates, sometimes with multiple outbreak waves. Endogenous risk perceptions create an important negative feedback that leads most countries to converge to effective reproduction numbers, $R_E \approx 1$: $R_E > 1$ leads to rapid growth in cases and mortality, increasing perceived risk and the (re)imposition of NPIs that bring R_E down; $R_E < 1$ lowers cases and deaths, leading to erosion of perceived risk and reduced adherence to NPIs that lead to more cases.

Critically, however, R_E settles around 1 at very different quasi-steady state infection rates across nations: those with high responsiveness to risk settle at $R_E \approx 1$ with very low incidence, while those with lower responsiveness settle at $R_E \approx 1$ with infection rates up to two orders of magnitude higher (Figure 6C). By March 2021, simulated R_E values generally converge to ≈1 (mean=0.93, σ=0.19, MIQR=0.051), indicating comparable levels of contact reduction across nations. Contrast that with infection rates in Scenario I, for instance: Ethiopia (156 daily infections/100,000 people; R_E = 1.32), Japan (0.291/100,000; 0.889), Poland (3.24/100,000; 1.01), and the USA (31/100,000; 1.12).

<Figure 6 Here>

The scenarios demonstrate the sensitivity of outcomes to testing and responses to perceived risk and should not be interpreted as predictions. Stronger behavioral and policy responses to perceived risk will significantly reduce future cases while lax responses and normalization of risks can lead to large rebound outbreaks (Figure 6D).

Robustness and boundary conditions

We conducted several analyses to assess the robustness of the results. (A) We ensured MCMC chains had converged (97% of Gelman-Rubin convergence statistics were below 1.2 and 90% under 1.1). (B) We varied the priors for cross-country parameter variances to 4 and 0.25 times the base values, resulting in <3% change across historical measures, though scenario results for a few countries are more sensitive (S7 provides details). (C) To see if any country disproportionately affects the outcomes we repeated the analysis using three different samples, excluding the top 5 countries by i) estimated cases, ii) reported cases, and iii) population. Average outcomes across the remaining countries changed

less than 1% (see S7) (D) We assessed the sensitivity of results to the parameters set from prior research by calculating the elasticities of key outcomes to these parametric assumptions. Across metrics all elasticities are less than 1. The largest (≈0.5) is for the impact of test sensitivity; greater sensitivity reduces underestimation.

These robustness tests do not address a few limitations which should temper the interpretation of the results. We do not represent within-nation heterogeneity that may affect the course of the epidemic, especially in diverse nations (e.g., USA) (*25*). We model IFR as depending on age distribution and hospitalization, omitting how well different nations protect vulnerable subpopulations. The model aggregates behavioral and government policy responses, and does not represent the effectiveness of specific NPIs. Finally, without explicit travel networks our results may under-estimate the risk of re-introduction of the disease where it has been contained.

Discussion

Modeling testing and hospitalization based on symptom severity relative to capacity, together with endogenous risk perceptions and responses, enables us to estimate the actual toll of COVID-19 relative to reported data. We find prevalence and mortality are substantially underestimated: across the 86 nations for which data are available, estimated cumulative COVID cases are 10.5 greater than official reports, with under-reporting across nations spanning three orders of magnitude. We find deaths are 1.47 times larger than official reports, yielding an IFR to date of ≈0.65%, consistent with growing evidence (*10, 40*). Substantial cross-national variation in IFR arises from differences in population age structure, and in the burden of severe cases relative to hospital capacity, highlighting the importance of limiting case growth. Further, despite underreporting, cumulative cases constitute small fractions of the populations, so herd immunity remains distant (S5 provides details).

Importantly, the large differences across nations are explained well without exogenous time-varying parameters and with parameters characterizing SARS-CoV-2 disease that are consistent with prior research and are similar across nations. We estimate that approximately half of infections are asymptomatic, consistent with estimates from smaller samples (*1, 11, 12*), with asymptomatic individuals estimated to be about a third as infective as symptomatic patients.

The wide variation across nations arises endogenously. First, the growth rate, timing, and size of initial outbreaks depend strongly on the magnitude of behavioral and policy responses to perceived risk, and the lags in forming and relaxing those perceptions, which we find vary notably across countries. Second, inadequate early testing leads to greater underestimation of prevalence, and thus later and weaker responses, causing faster epidemic growth, further outstripping testing and treatment capacity. These feedbacks amplify initial differences in initial reproduction rates and testing across nations, generating the observed heterogeneity.

Consequently, we find greater testing early in the pandemic would have avoided over 200,000 deaths, more than 30% of the estimated total through 10 July 2020. Projections through 20 March 2021 show that modest reductions in transmission through NPIs can lead to large reductions in cumulative cases and deaths.

However, the endogenous dynamics of risk perception mean initial containment can lead to erosion of NPI policies and adherence to them, generating the rebound outbreaks already seen in some nations. After controlling the initial peak, most countries settle into a quasi-steady state with the effective reproduction number settling near 1. However, long-term infection rates vary substantially, depending on national responsiveness to risk which conditions the infection rates at which $R_E \approx 1$ is reached.

Accordingly, absent stronger country-level responses, or breakthroughs in vaccination or treatment, the outlook remains grim, with a few large countries experiencing troublingly large steady state cases and deaths.

References and notes

1. D. F. Gudbjartsson *et al.*, Spread of SARS-CoV-2 in the Icelandic population. *New England Journal of Medicine*, (2020).
2. M. Roser, H. Ritchie, E. Ortiz-Ospina, J. Hasell, in *Our World in Data.* (2020).
3. W. Wang *et al.*, Detection of SARS-CoV-2 in different types of clinical specimens. *Jama* **323**, 1843-1844 (2020).
4. Y. Fang *et al.*, Sensitivity of chest CT for COVID-19: comparison to RT-PCR. *Radiology*, 200432 (2020).
5. Y. Li *et al.*, Stability issues of RT-PCR testing of SARS-CoV-2 for hospitalized patients clinically diagnosed with COVID-19. *J Med Virol* **92**, 903-908 (2020).
6. R. Xu *et al.*, Weather Conditions and COVID-19 Transmission: Estimates and Projections. *medRxiv*, (2020).
7. G. Onder, G. Rezza, S. Brusaferro, Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy. *JAMA*, (2020).
8. W. J. Guan *et al.*, Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl J Med* **382**, 1708-1720 (2020).
9. Z. Wu, J. M. McGoogan, Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. *Jama* **323**, 1239-1242 (2020).
10. T. W. Russell *et al.*, Estimating the infection and case fatality ratio for coronavirus disease (COVID-19) using age-adjusted data from the outbreak on the Diamond Princess cruise ship, February 2020. *Euro Surveill* **25**, (2020).
11. E. Lavezzo *et al.*, Suppression of COVID-19 outbreak in the municipality of Vo, Italy. *medRxiv*, (2020).
12. K. Mizumoto, K. Kagaya, A. Zarebski, G. Chowell, Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. *Euro Surveill* **25**, (2020).
13. D. Sutton, K. Fuchs, M. D'Alton, D. Goffman, Universal Screening for SARS-CoV-2 in Women Admitted for Delivery. *N Engl J Med* **382**, 2163-2164 (2020).
14. X. Hao *et al.*, Reconstruction of the full transmission dynamics of COVID-19 in Wuhan. *Nature*, (2020).
15. R. Li *et al.*, Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV2). *Science*, (2020).
16. H. Salje *et al.*, Estimating the burden of SARS-CoV-2 in France. *Science* **369**, 208-211 (2020).
17. S. M. Moghadas *et al.*, The implications of silent transmission for the control of COVID-19 outbreaks. *Proc Natl Acad Sci U S A*, (2020).
18. J. T. Wu, K. Leung, G. M. Leung, Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study. *Lancet* **395**, 689-697 (2020).

19. S. M. Kissler, C. Tedijanto, E. Goldstein, Y. H. Grad, M. Lipsitch, Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period. *Science* **368**, 860-868 (2020).
20. S. Hsiang *et al.*, The effect of large-scale anti-contagion policies on the COVID-19 pandemic. *Nature*, (2020).
21. M. Chinazzi *et al.*, The effect of travel restrictions on the spread of the 2019 novel coronavirus (COVID-19) outbreak. *Science*, (2020).
22. N. W. Ruktanonchai *et al.*, Assessing the impact of coordinated COVID-19 exit strategies across Europe. *Science*, (2020).
23. P. G. T. Walker *et al.*, The impact of COVID-19 and strategies for mitigation and suppression in low- and middle-income countries. *Science*, (2020).
24. S. Flaxman *et al.*, Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe. *Nature*, (2020).
25. T. Britton, F. Ball, P. Trapman, A mathematical model reveals the influence of population heterogeneity on herd immunity to SARS-CoV-2. *Science*, (2020).
26. M. Gatto *et al.*, Spread and dynamics of the COVID-19 epidemic in Italy: Effects of emergency containment measures. *Proc Natl Acad Sci U S A* **117**, 10484-10491 (2020).
27. S. M. Moghadas *et al.*, Projecting hospital utilization during the COVID-19 outbreaks in the United States. *Proc Natl Acad Sci U S A* **117**, 9122-9126 (2020).
28. L. Lopez, X. Rodo, The end of social confinement and COVID-19 re-emergence risk. *Nat Hum Behav* **4**, 746-755 (2020).
29. H. Rahmandad, K. Hu, Modeling the rework cycle: capturing multiple defects per task. *Syst Dynam Rev* **26**, 291-315 (2010).
30. N. M. Linton *et al.*, Incubation Period and Other Epidemiological Characteristics of 2019 Novel Coronavirus Infections with Right Truncation: A Statistical Analysis of Publicly Available Case Data. *J Clin Med* **9**, (2020).
31. A. Gelman, J. Hill, *Data analysis using regression and multilevel/hierarchical models*. (Cambridge university press, 2006).
32. J. A. Vrugt *et al.*, Accelerating Markov chain Monte Carlo simulation by differential evolution with self-adaptive randomized subspace sampling. *International Journal of Nonlinear Sciences and Numerical Simulation* **10**, 273-290 (2009).
33. D. P. Oran, E. J. Topol, Prevalence of Asymptomatic SARS-CoV-2 Infection: A Narrative Review. *Ann Intern Med*, (2020).
34. D. M. Weinberger *et al.*, Estimation of Excess Deaths Associated With the COVID-19 Pandemic in the United States, March to May 2020. *JAMA Intern Med*, (2020).
35. S. H. Woolf, D. A. Chapman, R. T. Sabo, D. M. Weinberger, L. Hill, Excess Deaths From COVID-19 and Other Causes, March-April 2020. *JAMA*, (2020).
36. A. Basu, Estimating The Infection Fatality Rate Among Symptomatic COVID-19 Cases In The United States. *Health Aff (Millwood)*, 101377hlthaff202000455 (2020).
37. A. Pan *et al.*, Association of Public Health Interventions With the Epidemiology of the COVID-19 Outbreak in Wuhan, China. *JAMA*, (2020).
38. S. Pei, S. Kandula, J. Shaman, Differential Effects of Intervention Timing on COVID-19 Spread in the United States. *med*R*xiv*, (2020).
39. D. K. Chu *et al.*, Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis. *Lancet* **395**, 1973-1987 (2020).
40. R. Verity *et al.*, Estimates of the severity of coronavirus disease 2019: a model-based analysis. *The Lancet infectious diseases*, (2020).

Acknowledgements: We thank Tom Fiddaman and Ventana Systems for access to the Vensim parallel simulation engine; Stephen Eubank, Navid Ghaffarzadegan, and Madhav Marathe for

thoughtful comments on an earlier draft; X.H. Chan and K. Jani for sharing clinical insights; and Nezam Jazayeri for assistance with graphs. **Author contributions**: HR designed the study; HR and TYL collected the data; HR and TYL conducted the analysis; HR, JS, TYL revised the model and prepared the manuscript. **Competing interests**: Authors declare no competing interests. **Data and materials availability**: Supplementary materials provide model documentation and full estimates. All data, code, and simulation models are available at: https://github.com/tseyanglim/CovidGlobal

Supplementary Materials:

S1 MODEL STURCUTRE AND KEY FORMULATIONS

S2 ESTIMATION METHOD

S3 VALIDATION OF ESTIMATION FRAMEWORK

S4 DATA PRE-PROCESSING

S5 EXTENDED RESULTS

S6 OUT OF SAMPLE PREDICTION TEST

S7 SENSITIVITY ANALYSIS

S8 COMPLETE MODEL DOCUMENTATION

Figures S1-S12

Tables S1-S8



Figure 1- Expanded SEIR model for each country. Key state variables are represented in rectangles.



Figure 2-Simulated (thick solid) vs. data (dotted and dashed) for reported cases (blue; right axis, thousands/day) and deaths (red; left axis; deaths/day) in countries with more than 30 million population and 30,000 confirmed cases by 10 July 2020.



Figure 3-Country level estimates. A) Ratio of estimated to reported cases (blue circles; left log scale) and deaths (red squares; right log scale. B) Estimated infection fatality rates (%).



Figure 4- Expected case undercount ratio as a function of testing and infection rates (underlying colormap; includes contour levels; calculated based on mean estimated parameters across nations). Overlay: historical trajectories of 6 countries (selected for variance in testing and size of population and infection) showing estimated true daily infections and daily tests performed (averaged over 15 day moving window for smoothness). Markers are one week apart, signaling the transition speed across different regions of input space, with final points on July 10th marked by gray stars. Logarithmic Scales.



Figure 5- Most likely estimate (solid lines) of cumulative cases (A; blue) and deaths (B; red) compared with most likely counterfactual (dashed line) in which testing rises to 0.1% of population per day starting 11 March 2020. Thin lines show 95% CIs.



Figure 6- Projections and comparisons across three scenarios. A) True cumulative cases (most likely and 95% CI) across 86 countries until Spring 2021 under scenarios I (baseline; solid line), II (high testing; dashed), and III (modestly responsive; dotted). B) Median (95% CI) true cumulative cases (blue; left axis) and deaths (red; right axis) as % of population, projected for the end of Winter 2021 under Scenario I (Logarithmic Scale) C) Median (95% CI) daily infections (blue; left axis) and deaths (red; right axis) as % of population, projected and averaged for the last month of Winter 2021 under Scenario I (Logarithmic Scale) D) Median (95% CI) reductions in effective contact rate right after introduction of enhanced response in Scenario III (compared with Scenario I, in %, red squares; right axis) and projected cumulative case percentages (end of Winter 2021); 30 countries with top reductions.

Supplementary Materials for

Estimating COVID-19 under-reporting across 86 nations: implications for projections and control

Authors: Hazhir Rahmandad[1*], Tse Yang Lim[1], John Sterman[1]

*Correspondence to: hazhir@mit.edu

This PDF file includes:

S1 MODEL STRUCTURE AND KEY FORMULATIONS 3
Population Groups and Transmission Dynamics 3
Modeling the Severity of Symptoms 5
Testing 6
Hospitalization 9
Infection Fatality Rates 10
Risk Perception and Responses 11
Summary of Key Equations and Parameters 11
S2 ESTIMATION METHOD 15
Overview of the Approach 15
The Fit to Time Series for Cases and Deaths 15
Incorporating the coherence of parameters across countries 16
Excess mortality penalty 19
Numerical Methods 19
S3 VALIDATION OF ESTIMATION FRAMEWORK 22
S4 DATA PRE-PROCESSING 26
S5 EXTENDED RESULTS 32

Quality of fit measures 32
Estimates for true magnitude of epidemic 36
Excess deaths 37
Maximum reproduction number 38
Time to herd immunity 39
Parameter estimates 40
Future projections 43
S6 OUT OF SAMPLE PREDICTION TEST 44
S7 SENSITIVITY ANALYSIS 48
Impact of Cross-country Parameter Variances 48
Sensitivity to Parametric Assumptions 52
Sensitivity of results to exclusion of major countries 54
S8 COMPLETE MODEL DOCUMENTATION 56
S9 References 74

List of Figures

Figure S1- Key population stocks and flows. 3
Figure S2- Overview of model's mechanisms. 5
Figure S3- Schematic overview of zero-inflated Poisson process and test allocation. 8
Figure S4-Country-level parameter estimates and 95% credible intervals from synthetic estimation exercise 25
Figure S5- Comparison of data and simulation. 35
Figure S6- Estimates and 95% credible intervals for true magnitude of epidemic. 36
Figure S7- Ratio of estimated excess deaths to reported excess deaths. 37
Figure S8- Maximum reproduction number R_E for each country's outbreak. 38
Figure S9- Time to 80% cumulative infection 39
Figure S10- Parameter estimates and 95% credible regions for country-specific parameters. 42
Figure S11- Country level projections until Spring 2021 in scenario I. 43
Figure S12-Predictions from the June 16th model for June 17-July 10 interval. 45

List of Tables

Table S1- Mapping between full variable names and their short form 12
Table S2- Estimated model parameters 18
Table S3- Measures of fit between data and simulations for different countries. 33
Table S4- Quality of fit for future projections compared to when data is available. 46
Table S5- Impact of decreasing assumed cross-country parameter variances by a factor of four 49
Table S6- Impact of increasing assumed cross-country parameter variances by a factor of four. 50
Table S7- Overview of parametric sensitivity results 54
Table S8-Sensitivity of outcomes (in percentage change from baseline) to exclusion of top five countries 55

S1 MODEL STRUCTURE AND KEY FORMULATIONS

The model simulates the evolution of COVID-19 epidemic, risk perception and response, testing, hospitalization, and fatality at the level of a country. Here we explain key equations and structures in each sector, followed by complete listing of model equations and parameters in S8.

Population Groups and Transmission Dynamics

The model is a derivative of the well-known SEIR (Susceptible, Exposed, Infectious, Recovered) framework for simulating infection dynamics. Figure S1 provides an overview of key population groups and the population movements among them[1].



Figure S1- Key population stocks and flows. Rectangles represent stocks (state variables), while arrows and valves represent the flows between them (state transitions).

The *Susceptible* population (S) transitions to the *Pre-Symptomatic Infected* state (P) based on the *Infection Rate* (r_{SP}). After an average *Incubation Period* (τ_P), these pre-symptomatic infected transition into the *Infected Pre-Detection* (I_P) state. After a further average *Onset to Detection Delay* (τ_T), this group splits among multiple pathways. First, if tested positive for COVID-19, they transition into either *Infectious Confirmed Not Hospitalized* (I_C) or *Hospitalized Infectious Confirmed* (I_{CH}). Anyone not tested positive, whether for lack of testing or erroneous test results, transitions into either *Hospitalized Infectious Unconfirmed* (I_{UH}) or *Infectious Unconfirmed Post-Detection* (I_U). We assume demand for testing and hospitalization are driven by symptoms, so all asymptomatic patients will be in the latter category.

From these Infectious categories, resolution flows ($r_{...}$) take individuals to either Recovered ($R_{...}$) or Dead ($D_{...}$) states, with corresponding subscripts $_U$, $_C$, $_{CH}$, and $_{UH}$ for stocks and $_{UU}$, $_{UHCH}$ etc. for flows. Given the differences in severity and potential survival extension due to hospitalization, we distinguish between resolution delay for those in hospital (*Hospitalized Resolution Time;* τ_H) and those not

[1] In the equations below we use short-hands to simplify mathematical notations. The full model documentation uses full variable names. Table S1 provides the mapping between the short-hands and the full names, as well as the sources and equations for those variables and parameters discussed below.

hospitalized (*Post-Detection Phase Resolution Time*; τ_R). We use first order exponential delays for all lags, though sensitivity analyses showed very little impact of using higher order delays.

The *Infection Rate* (r_{SP}) controls the flow from S to P and depends on *Infectious Contacts* (C_I), fraction of total *Population* (N) that is susceptible, and *Weather Effect on Transmission* (W). The latter is a function of R_W, the country-level projections for impact of weather on COVID-19 transmission risk year-round developed by Xu and colleagues (*1*) and a parameter, *Sensitivity to Weather* (s_W), to be estimated:

$$r_{SP} = C_I W \left(\frac{S}{N}\right) \quad (1)$$

$$W = R_W^{s_W} \quad (2)$$

Infectious contacts depend on the *Reference Force of Infection* (β), various infectious sub-populations (and their relative transmission rates; m_a for asymptomatic and m_T for confirmed), and *Contacts Relative to Normal* (F_C), which captures behavioral and policy responses as a fractional multiplier to baseline infectious contacts:

$$C_I = \beta F_C(m_a(P^a + I_P^a + I_U^a) + I_P^s + I_U^s + P^s + I_{UH} + m_T(I_{CH} + I_C)) \quad (3)$$

In this equation we separate various stocks (of I and P) into asymptomatic (a superscript) and symptomatic (s superscript). That distinction is treated analytically using a zero-inflated Poisson distribution that is discussed in the next section. In light of evidence on the short serial interval for COVID-19, likely below the incubation period (*2, 3*), we do not distinguish the infectivity of pre-symptomatic individuals from those post onset. Contagion dynamics start from *Patient Zero Arrival Time*, T_0, another estimated parameter. The key mechanisms regulating the population flows among these stocks are discussed below, and a schematic of important relationships is provided in Figure S2.

Five parameters are estimated in the equations discussed above. One of them (s_W) is global (i.e. assumed identical across countries; see the estimation section below for details on the distinction between global and country-specific parameters) and the remaining four are country-specific: β, m_T, m_a, and T_0.



Figure S2- Overview of model's mechanisms. Major feedback loops are identified as Balancing (or Negative feedback; B) and Reinforcing (or Positive feedback; R).

Modeling the Severity of Symptoms

COVID-19 infection varies in acuity, from asymptomatic to life-threatening. Acuity of disease affects not-only baseline fatality risk, but also testing and hospitalization decisions which impact official records of infection and fatality rates. Since movement between population groups via testing or hospitalization is itself a function of acuity, to allow for consistent inference of mean acuity across different population groups, we use an analytical framework to track acuity levels. This framework, which we adapted from prior research (*4*), obviates the need to disaggregate the population by different acuity levels (which would prohibitively raise the computational costs for estimation).

Specifically, we represent acuity using a zero-inflated Poisson distribution. This distribution combines two subpopulations – one with Poisson-distributed acuity levels with mean *Covid Acuity* (α_C), and another *Additional Asymptomatic Fraction* with zero acuity, which is the zero-inflated component. The sum of those with zero acuity from the Poisson part of the population and the second group is the *Total Asymptomatic Fraction* (p_a). We assume this asymptomatic group is not given priority in testing or hospitalization, and is not at risk of death. Thus they will always follow the $S \xrightarrow{r_{SP}} P \xrightarrow{r_{PP}} I_P \xrightarrow{r_{IU}} I_U \xrightarrow{r_{UU}} R_U$ pathway. The pathways for the remaining population depend on acuity and its impacts on testing, hospitalization, and death. Note that the concept of acuity defined here only needs to have a monotonic relationship with tangible symptoms and risk factors and it does not have a one-to-one relationship with any real world measure of acuity, and as such is better seen as a mathematical construct that informs modeling rather than a real-world variable with clinical definition.

From this framework two parameters, a and α_C, are estimated as country specific parameters with limited variability across countries.

Testing

The testing sector reads the *Active Test Rate* (T_t) for each country as exogenous input data (see appendix S3 for pre-processing details for this data). A fraction of this total test rate, typically small, is allocated to post-mortem testing of COVID-19 victims who have not been previously confirmed (*Post Mortem Tests Total*, T_{PM}). Specifically, of the deaths of unconfirmed infectious individuals (whether hospitalized or not), a certain *Fraction of Fatalities Screened Post Mortem* (n_{PM}) will be identified true post-mortem tests. We anchor the n_{PM} to *Fraction Covid Death In Hospitals Previously Tested* (n_{DCH}). The rationale for this anchoring is that on the margin if there are many unidentified COVID patients in hospitals, the chances are that the system lacks enough testing capacity and thus post-mortem testing should also be less thorough:

$$n_{PM} = n_{DCH} \tag{4}$$

We experimented other functional forms with a free parameter connecting the two constructs, but following our conservative estimation principle decided against including that free parameter in the final model. We feared that absent clear observables to identify this additional parameter (e.g. on country-specific policies regulating post-mortem testing) the degree of freedom would improve the fit but potentially for the wrong reason.

The remaining *Testing Capacity Net of Post Mortem Tests* ($T_{Net} = T_t - T_{PM}$) is allocated to test demand from two sources. First, symptomatic COVID patients leaving the pre-detection (I_P) phase may seek testing (*Positive Candidates Interested in Testing Poisson Subset*: $M_C = \frac{I_P}{\tau_T}(1 - p_a)$). Second, COVID-negative individuals may seek testing due to various perceived risks and other conditions with overlapping symptoms such as common cold and influenza-like illnesses (M_N, *Potential Test Demand from Susceptible Population*). This "negative" demand includes a *Baseline Daily Fraction Susceptible Seeking Tests* (n_{ST}) of the population not previously tested positively (N_U), and increases with the *Recent Detected Infections* (T_{PIR}), which is an exponentially weighted moving average of *Positive Tests of Infected* (T_{PI}). COVID-positive and COVID-negative sources of demand add up to create the overall *Testing Demand* (M_T):

$$M_N = n_{ST} N_U + m_{IT} T_{PIR} \tag{5}$$

$$M_T = M_N + M_C \tag{6}$$

Where the *Multiplier Recent Infections to Test* (m_{IT}), captures the sensitivity of negative test demand to recent infection reports.

To allocate the available tests (T_{Net}) between these two sources of demand, we use an analytical logic that allocates testing based on acuity of symptoms. The basic idea is that through self selection and screening by testing centers, people who have more symptoms or other signals that correlate with COVID infection (e.g. high exposure risk) are more likely to be tested. We assume each unit of acuity increases the likelihood that an individual gets tested, based on a variable *Prob Missing Symptom*, p_{MS}.

This variable represents the probability that each acuity unit fails to convince the testing decision process to test a given individual, i.e. how selectively and sparingly tests are conducted. Specifically, in this model an individual with *k* acuity units is tested with probability:

$$p(test|k\ symptoms) = 1 - p(missing\ k\ symptoms) = 1 - p_{MS}^{k} \quad (7)$$

We assume the negative test demand is coming from a population with a Poisson-distributed, unit average acuity level (α_N=1) for symptoms of non-COVID influenza-like illnesses. The test demand from COVID patients also comes from a Poisson distribution of acuity, but with mean α_C. With the Poisson distribution and given a level of α and p_{MS}, one can calculate the fraction of each demand source that would be tested:

$$p(getting\ test) = 1 - p(not\ being\ tested) = 1 - \sum_{k=0}^{k=\infty} \frac{e^{\alpha}\alpha^{k}}{k!} p_{MS}^{k} = 1 - e^{-\alpha(1-p_{MS})} \quad (8)$$

We therefore need to find the p_{MS} that allows test supply to match demand that is satisfied, specifically, by solving the following equation for p_{MS}*:

$$T_{Net} = M_N(1 - e^{-\alpha_N(1-p*_{MS})}) + M_C(1 - e^{-\alpha_C(1-p*_{MS})}) \quad (9)$$

Figure S3 provides a graphical summary of the zero-inflated Poisson symptom and testing framework. In this figure testing outcomes are graphed for a population where 10% are COVID-positive, assuming that *Covid Acuity*, α_C, is 6, and with two different levels of p_{MS} (=0.8 and 0.95). For this figure we also assume a 55% asymptomatic fraction for COVID patients. Even with testing that prioritizes patients with more symptoms, and despite the large difference in symptom frequency between COVID patients and negative cases, the majority of tests are allocated to negative cases with a few symptoms. COVID patients with multiple symptoms are likely to be identified if P_{MS} is not very large, but when total demand for testing (i.e. the sum of all bars with symptoms>0) is large, P_{MS} , found from solving equation 9, may be close to 1, excluding many COVID patients with multiple symptoms and thus higher risks of fatality.



Figure S3- Schematic overview of zero-inflated Poisson process and test allocation. Red bars represent COVID-positive individuals and blue ones are COVID-negative. Asymptomatic fraction is assumed to be 55% for COVID patients with the symptomatic cases following a Poisson distribution with mean 6. Color coded bars signal fraction of tested individuals with different levels of probability of missing symptoms, P_{MS}.

Having solved for p^*_{MS} (numerically), we analytically calculate the average acuity level for those positively tested (α_{CP}: *Average Acuity of Positively Tested*) and those either not tested or having received a false negative result (α_{CN}). Specifically, if test sensitivity was 100%, the average acuity for those not tested would be:

$$\alpha_{Not\ Tested} = \sum_{k=0}^{k=\infty} k \frac{e^{\alpha}\alpha^k}{k!} {p^*_{MS}}^k = \alpha p^*_{MS} e^{-\alpha(1-p*_{MS})} \quad (10)$$

The acuity level for those tested could then be found based on the conservation of total acuity across those positively tested and those not. Starting with this basic specification we further account for the *Sensitivity of Covid Test* (s_T) to calculate the values of α_{CP} and α_{CN}. We parametrize sensitivity at 70%, which is the estimated sensitivity for the PCR-based tests used as the primary diagnosis method of current infections of COVID-19 (*5, 6*).

Overall, the testing rates that are determined by solving for p^*_{MS}, combined with sensitivity of tests, inform the fraction of COVID positive individuals transitioning from pre-detection (I_P) to confirmed

vs. unconfirmed states (I_C or I_{CH} vs. I_U or I_{UH}), while the calculated α values inform the likelihood of hospitalization and fatality rates, as discussed next.

The testing sector includes the following two country level parameters that are estimated: n_{ST}, m_{IT}.

Hospitalization

The hospitalization sector of the model starts with each country's *Nominal Hospital Capacity* (h_N) in total hospital beds. In practice, geographic variation in hospital density and demand creates imperfect matching of available beds with cases of COVID-19 at any point in time, e.g. because some potential capacity is physically distant from current COVID hotspots. This imperfect matching means some of the nominal hospital capacity is effectively unavailable at any time, especially in larger, less densely populated countries. We therefore calculate *Effective Hospital Capacity* (h_E) by considering geographic density of hospital beds (*Bed per Square Kilometer;* d_H):

$$h_E = h_N \left(\frac{d_H}{d_H^*}\right)^{s_{DH}} \tag{11}$$

Where the d_H^* represents a large *Reference Hospital Density* of 6.06 beds per km^2 (which is the value of d_H for South Korea). The parameter s_{DH} (*Impact of Population Density on Hospital Availability*) is estimated.

Effective capacity is allocated between *Potential Hospital Demand* (H_{CD}) from COVID-19 cases and the regular demand for hospital beds from all other conditions (which we assume equals pre-pandemic effective hospital capacity). We assume that COVID-19 patients will have higher priority for hospitalization compared to regular demand. Specifically, we assume that fraction of regular demand allocated (m_{HR}) would be the square of that for COVID demand (m_{HC}), $m_{HR} = m_{HC}^2$, and solve the resulting hospital capacity allocation problem analytically:

$$h_E = h_E m_{HR} + H_{CD} m_{HC} \Rightarrow m_{HC} = \frac{-H_{CD} + \sqrt{H_{CD}^2 + 4h_E^2}}{2h_E} \tag{12}$$

We determine the COVID demand for hospitalization based on a screening process similar to that for testing. Two types of COVID patients may seek hospitalization: those with confirmed test results and those without. The former are more likely to seek hospital treatment. We first calculate a parameter analogous to p_{MS} in the testing sector that informs the demand from confirmed COVID patients for hospitalization. This parameter, the *PMAS Confirmed for Hospital Demand* (p_{MHC}) is determined based on acuity level of confirmed (α_{CT}) and *Reference COVID Hospitalization Fraction Confirmed* (r_H), an estimated parameter capturing the overall need for hospitalization among COVID patients:

$$p_{MHC} = (1 - r_H)^{\frac{1}{\alpha_{CT}}} \tag{14}$$

For unconfirmed COVID patients we scale the analogue of this parameter (p_{MHU}) based on how much priority non-COVID patients generally receive:

$$p_{MHU} = p_{MHC} + (1 - p_{MHC})(1 - m_{HR}) \tag{15}$$

This formulation ensures that: 1) Confirmed COVID patients are more likely to be hospitalized, but also that 2) if there is ample hospital capacity (m_{HR}~1), then confirmed and unconfirmed COVID patients will receive similar priority for the same level of acuity. In short, the $p_{M.}$ values determine hospital demand by confirmed and unconfirmed COVID patients, which add up to H_{CD}. The latter determines the fraction of hospital demand that is met. Analogous to the testing sector, this fraction along with demand determines the flow of individuals from the pre-detection (I_P) state to hospitalized vs. non-hospitalized states (I_{CH} or I_{UH} vs. I_C or I_U). Matching demand to allocated capacity also allows us to calculate the realized *Probability of Missing Acuity Signal at Hospitals* (p^*_M) for confirmed and unconfirmed patients. As in the testing sector, those probabilities let us approximate for the expected acuity levels for COVID patients in and out of hospital, as well as tested vs. not-tested, i.e. α_{CT}, α_{CH}, α_U, and α_{UH}. These average acuity levels in turn inform fatality rates for each group.

The hospital sector includes two country level estimated parameter with limited variation across countries: s_{DH} and r_H.

Infection Fatality Rates

For patients in each of the $_U$, $_C$, $_{CH}$, and $_{UH}$ groups we specify the *Infection Fatality Rate* (f), as:

$$f_{(.)} = f_b \alpha_{(.)}^{s_f} s_{HF}(.) g_{Ag} \tag{16}$$

The parameter *Base Fatality Rate for Unit Acuity* (f_b) sets the baseline for fatality rate. *Sensitivity of Fatality Rate to Acuity* (s_f) determines how fatality changes with estimated acuity levels; more severe cases are expected to have higher fatality rates. Hospitalization reduces fatality rates, expressed as the relative *Impact of Treatment on Fatality Rate* (s_{HF}).

The g_{Ag} function incorporates the impact of age distribution on fatality rates. For age effect, we calculate a risk factor for each country. We use data from the World Bank on the age distribution of each country's population in 10-year age strata to calculate an age-weighted average of the IFRs for COVID patients by 10-year age group reported in prior work (*7*). We normalize this age-weighted average IFR against its value for China, where the data on IFRs by age group were originally recorded. Normalizing in this way means the age effect is not sensitive to any systematic over- or under-estimation of the IFR in prior work, only to the relative risk by age group. The resulting normalized age effect ranges from 0.271 (Kenya, median age ~20 years) to 2.368 (Japan, median age ~48 years). Given the well-established impact of age on fatality, this factor is directly multiplied into the infection fatality equations.

Overall, the fatality sector includes three parameters that are estimated at the country level, with limited variance across countries, those are: f_b, s_{HF}, and s_f.

Note on comorbidities and fatality: We also explored including three comorbidities but found the estimates unreliable and therefore they are not included in the main specification of the model. Those comorbidities include obesity, chronic disease, and liver disease. The effects we explored for each were: $g_{(.)} = d_{(.)}^{s_{(.)f}}$, where we used the following country-level indicators from the World Health Organization (*8*), normalized by the average across all countries ($d_{(.)}$):

For obesity: Prevalence of obesity among adults, BMI ≥30 (age-standardized estimate) (%)

For chronic health issues: Probability (%) of dying between age 30 and exact age 70 from any of cardiovascular disease, cancer, diabetes, or chronic respiratory disease

For liver disease: Liver cirrhosis, age-standardized death rates (15+), per 100,000 population

Risk Perception and Responses

In equation 3 we noted that *Contacts Relative to Normal* (F_C) regulates infection rates. This factor ranges between a minimum (*Min Contact Fraction*; c_{Min}) and 1 as a function of the relative *Utility from Normal Activities* (U_N) compared to *Utility from Limited Activities* (U_L) in light of additional risks associated with normal activity patterns:

$$F_C = \frac{F}{F(0)}(1 - c_{Min}) + c_{Min} \tag{17}$$

$$F = \frac{U_N}{U_N + U_L} \tag{18}$$

The utilities from normal and limited activities are specified as $U_N = e^{s_C(1-L_R)}$ and $U_L = e^{0.5 s_C}$. The former depends on the *Perceived Risk of Life Loss* (L_R) while the latter depends only on the *Sensitivity of Contact Reduction to Utility* (s_C). L_R adjusts to an underlying *Indicated Risk of Life Loss* (L_R^*) with a time constant that is asymmetric, i.e. *Time to Upgrade Risk* (τ_{RU}) could be different from *Time to Downgrade Risk* (τ_{RD}). The L_R^* itself depends on *Perceived Hazard of Infection* (Z_{IP}) from pursuing normal activities, the perceived risk of loss of life in case of infection (p_D, for which we use the global ratio of cumulative deaths to cases to date); a discount rate to turn daily costs to life-long ones (γ=0.03/year); and an estimated parameter to capture variations in risk communication, policies, and risk perceptions across countries (*Dread Factor in Risk Perception*, λ):

$$\frac{dL_R}{dt} = \frac{L_R^* - L_R}{\tau_{R.}} \tag{19}$$

$$L_R^* = \frac{Z_{IP}\lambda p_D}{\gamma} \tag{20}$$

Finally, the *Perceived Hazard of Infection* (Z_{IP}) is an average of reported daily hazard of infection (with the weight *Weight on Reported Probability of Infection,* w_R) and true hazard for symptomatic infections which individuals may perceive through word of mouth and their social networks.

Overall, the risk perception and response sector includes the following five country-specific parameters that are estimated: c_{Min}, τ_{RU}, τ_{RD}, λ, and w_R.

Summary of Key Equations and Parameters

Table S1 summarizes the main equations discussed in S1, providing the mapping between full variable names and the short forms. It also includes all estimated model parameters, as well as those specified based on prior research.

Table S1- Mapping between full variable names and their short form for the subset of variables and parameters discussed in S1. Also included are equations explained above and sources for other variables.

Short form	Full variable name	Equation/Source
T_t	Active Test Rate	Data (See S4 for pre-processing details)
m_{HC}	Allocated Fraction COVID Hospitalized	$\frac{-H_{CD}+\sqrt{H_{CD}^2+4h_E^2}}{2h_E}$
m_{HR}	Allocated Fration NonCOVID Hospitalized	m_{HC}^2
α_{CP}	Average Acuity of Positively Tested	See full documentation
f_b	Base Fatality Rate for Unit Acuity	Estimated
n_{ST}	Baseline Daily Fraction Susceptible Seeking Tests	Estimated
d_H	Bed per Square Kilometer	Data (*8*)
m_T	Confirmation Impact on Contact	Estimated
F_C	Contacts Relative to Normal	$\frac{F}{F(0)}(1-c_{Min})+c_{Min}$
α_C	Covid Acuity	Estimated
R_W	CRW	Use estimates from (*1*)
g_{AG}	Demographic Impact on Fatality Relative to China	Use estimates based on (*8, 9*)
γ	Discount Rate per Day	$8.2e^{-5}$ /Day
λ	Dread Factor in Risk Perception	Estimated
h_E	Effective Hospital Capacity	$h_N\left(\frac{d_H}{d_H^*}\right)^{s_{DH}}$
n_{DCH}	Fraction Covid Death In Hospitals Previously Tested	See full documentation
n_{PM}	Fraction of Fatalities Screened Post Mortem	n_{DCH}
I_{CH}	Hospitalized Infectious Confirmed	See full documentation
I_{UH}	Hospitalized Infectious Unconfirmed	See full documentation
τ_H	Hospitalized Resolution Time	20 Days
s_{DH}	Impact of Population Density on Hospital Availability	Estimated
s_{HF}	Impact of Treatment on Fatality Rate	Estimated
τ_P	Incubation Period	5 days
L_R^*	Indicated Risk of Life Loss	$L_R^*=\frac{Z_{IP}\lambda p_D}{\gamma}$
I_P	Infected pre Detection	See full documentation
I_U	Infected Unconfirmed Post-Detection	See full documentation
f(.)	Infection Fatality Rate (.)	$f_b\alpha_{(.)}^{s_f}s_{HF}(.)g_{Ag}$
r_{SP}	Infection Rate	$C_I W\left(\frac{S}{N}\right)$
I_C	Infectious Confirmed Not Hospitalized	See full documentation

C_I	Infectious Contacts	$\beta F_C(m_a(P^a + I_P^a + I_U^a) + I_P^s + I_U^s + P^s + I_{UH} + m_T(I_{CH} + I_C))$
c_{Min}	Min Contact Fraction	Estimated
m_{IT}	Multiplier Recent Infections to Test	Estimated
h_N	Nominal Hospital Capacity	Data
τ_T	Onset to Detection Delay	5 Days
T_0	Patient Zero Arrival Time	Estimated
Z_{IP}	Perceived Hazard of Infection	See full documentation
L_R	Perceived Risk of Life Loss	$\frac{dL_R}{dt} = \frac{L_R^* - L_R}{\tau_R}$
N	Population	Data (*10*)
M_C	Positive Candidates Interested in Testing Poisson Subset	$\frac{I_P}{\tau_T}(1-a)$
T_{PM}	Post Mortem Tests Total	See full documentation
τ_R	Post-Detection Phase Resolution Time	10 Days
H_{CD}	Potential Hospital Demand	See full documentation
M_N	Potential Test Demand from Susceptible Population	$n_{ST}N_U + m_{IT}T_{PIR}$
T_{PI}	Positive Tests of Infected	See full documentation
P	Pre-Symptomatic Infected	See full documentation
p_{MHC}	PMAS Confirmed for Hospital Demand	$(1-r_H)^{\frac{1}{\alpha_C}}$
p_{MHU}	PMAS Unconfirmed for Hospital Demand	$p_{MHC} + (1-p_{MHC})(1-m_{HR})$
p_{MS}	Prob Missing Symptom	From solution to equation 9
p_D	PseudoCFR	Data
T_{PIR}	Recent Detected Infections	See full documentation
r_H	Reference COVID Hospitalization Fraction Confirmed	Estimated
β	Reference Force of Infection	Estimated
d_H^*	Reference Hospital Density	Data (*8*)
m_a	Multiplier Transmission Risk for Asymptomatic	Estimated
s_T	Sensitivity of Covid Test	0.7
s_f	Sensitivity of Fatality Rate to Acuity	Estimated
s_C	Sensitivity of Contact Reduction to Utility	Estimated
s_W	Sensitivity to Weather	Estimated
S	Susceptible	See full documentation
T_{Net}	Testing Capacity Net of Post Mortem Tests	$T_t - T_{PM}$
M_T	Testing Demand	$M_N + M_C$
τ_{RD}	Time to Downgrade Risk	Estimated
τ_{RU}	Time to Upgrade Risk	Estimated
p_a	Total Asymptomatic Fraction	Estimated

U_L	Utility from Limited Activities	$e^{0.5sc}$
U_N	Utility from Normal Activities	$e^{sc(1-L_R)}$
w_R	Weight on Reported Probability of Infection	Estimated
W	Weather Effect on Transmission	R_W^{sw}

S2 ESTIMATION METHOD

Overview of the Approach

The model we estimate is nonlinear and complex, and any estimation framework is unlikely to have clean analytical solutions or provable bounds on errors and biases. Therefore, in designing our estimation procedure we apply 3 guideposts: 1) Being conservative by incorporating uncertainties. 2) Avoid over-fitting; and 3) Enhance generalizability and robustness of estimates and projections. To these ends: we use a likelihood function that accommodates overdispersion and autocorrelation (negative binomial); we utilize a hierarchical Bayesian framework to couple parameter estimates across different countries which reduces the risk of over-fitting the data; and we use the conceptual definitions of parameters and their expected similarity across countries to inform the priors for the magnitude of that coupling across countries. Compared to more common choices in similar estimation settings (e.g. use of Gaussian likelihood functions), these choices tend to widen the credible regions for our estimates and reduce the quality of the fit between model and data. In return, we think the results may be more reliable for projection, more informative about the underlying processes, and better reflective of uncertainties in such complex estimation settings. We also conduct a validation test of our estimation framework using synthetic data in section S3.

The model is a deterministic system of ordinary differential equations with a set of known and unknown parameters. The known parameters are those specified based on the existing literature and do not play an active role in estimation. The unknown parameters can be categorized into those that vary across different countries and those that are the same across all countries (i.e. "general" parameters). The estimation method is designed to identify both the most likely value and the credible regions for the unknown parameters, given the data on reported cases and deaths (and for a subset of countries, the excess deaths). This is done through a combination of estimating the most likely parameter values in a likelihood based framework, and using Markov Chain Monte Carlo simulations to quantify the uncertainties in parameters and projections.

We first introduce the 3 different components of the likelihood function we use: the fit to time series data, the random effects component coupling country-level parameters, and the penalty for excess mortality. Then we explain the implementation details.

The Fit to Time Series for Cases and Deaths

Define model calculations for expected reported cases and deaths for country i as $\mu_{ij}(t)$ (with index j specifying cases and deaths) and the observed data for those variables as $y_{ij}(t)$; the country-level vector of unknown parameters as $\boldsymbol{\theta_i}$ and the general unknown parameters as $\boldsymbol{\phi}$. Note that $\boldsymbol{\theta_i}$ vector includes several parameters, each specifying an unknown model parameter, such as Impact of Treatment on Fatality, or Total Asymptomatic Fraction, for country i. The model can be summarized as a function f that produces predictions for expected cases and deaths for each country given the general and country-specific parameters:

$$\mu_{ij}(t) = f(\boldsymbol{\phi}, \boldsymbol{\theta_i}) \tag{21}$$

We use a negative binomial distribution to specify the likelihood of observing the y values given $\boldsymbol{\theta}$ and $\boldsymbol{\phi}$. Specifically, the logarithm of likelihood for observing the data series y given model predictions $\mu(\boldsymbol{\theta}, \boldsymbol{\phi})$ is:

$$LT(t|\boldsymbol{\phi},\boldsymbol{\theta}) = \sum_{ij} L1_{ij}(t) + L2_{ij}(t) + L3_{ij}(t) \quad (22)$$

where (dropping time index for clarity):

$$L1_{ij} = -\sum_{y_{ij}=0} \frac{\ln(1+\varepsilon_i\mu_{ij})}{\varepsilon_{ij}} \quad (23)$$

$$L2_{ij} = \sum_{y_{ij}>0} \sum_{k=0}^{y_{ij}-1} \ln\left(k + \frac{1}{\varepsilon_{ij}}\right) \quad (24)$$

$$L3_{ij} = \sum_{y_{ij}>0} [-\ln(y_{ij}!) - \left(y_{ij} + \frac{1}{\varepsilon_{ij}}\right)\ln(1+\varepsilon_{ij}\mu_{ij}) + y_{ij}\ln(\varepsilon_{ij}) + y_{ij}\ln(\mu_{ij}) \quad (25)$$

Summing the LT function over time provides the full (log) likelihood for the observed data given a parameterization of the model. The negative binomial likelihood function includes two parameters, μ and ε which determine the mean and the scaling/shape of the observed outcomes. The second parameter, ε, provides the flexibility needed fit outcomes with fat tails and auto-correlation. This parameter could itself be subject to search in the optimization process. Specifically, we assume that:

$$\varepsilon_{ij} = \varepsilon_i \varepsilon_j \quad (26)$$

Thus we create a (set of) country specific parameter(s) (ε_i) and two general parameters (ε_j) which should be estimated along with the conceptual model parameters. The country level scale (ε_i) implicitly assesses the reliability and inherent variability in country level reports, and the general ones inform the variability in case data vs. deaths. We augment the vectors $\boldsymbol{\phi}$ and $\boldsymbol{\theta}$ to include these scaling parameters as well.

Incorporating the coherence of parameters across countries

Up to this point we have not included any relationship among country specific parameters, $\boldsymbol{\theta_i}$. This independence assumption would allow parameters representing the same underlying concept to vary widely across different countries. Such treatment, by providing more flexibility, enhances the model's fit to historical data. However, it ignores the conceptual link that exists for a given parameter across countries, potentially allowing the model to fit the data for the wrong reasons (i.e. using parameter values that do not correspond to meaningful real world concepts). The result would likely be less reliable and also not robust for future projections. We therefore define a Hierarchical Bayesian framework to account for the potential dependencies among model parameters. Specifically, we assume the same conceptual parameters (e.g. Impact of Treatment on Fatality), across different countries, are coming from an underlying normal distribution with an unknown mean (to be estimated) and a pre-specified prior for the standard deviation. This assumption is similar to the use of "Random Effect" models common in regression frameworks, though we deviate from canonical random effect models by pre-specifying the standard deviation. In fact it is possible to estimate the standard deviation across countries as well (and to obtain better fits to data by including the additional degrees of freedom), but adding those degrees of freedom ignores qualitatively relevant insights about the level of coupling across different countries for each parameter, and thus results may fit the data better but for the wrong reasons. For example, some parameters, such as Patient Zero Arrival Time, could be very different across countries, whereas parameters reflecting innate properties of the SARS-CoV-2 virus itself (e.g. *Total Asymptomatic Fraction* (*a*)) or those determining fatality (e.g. *Base Fatality*

Rate for Unit Acuity (f_b)) should be very similar across different countries. Allowing the model to determine the variance for the latter will lead to better fits: the model can find baseline fatality rates that easily match fatality variations across countries, and would expand the corresponding variance parameter accordingly. However, as a result the estimation algorithm will have too easy a job: it will not require a precise balancing between hospitalization, impact of acuity on fatality, and post-mortem testing decisions to fit fatality data. Thus, the estimates may well be less informative, or further from true underlying processes and the general characteristics of the disease which we care about. Overall, our implementation of a hierarchical Bayesian estimation framework to account for the coupling among the variables may reduce the apparent quality of fit but offer more robust results better informing the underlying mechanisms.

The implementation of this random effect introduces another element to the overall likelihood function:

$$LC(\boldsymbol{\theta}) = -\sum_{ik} \frac{\left(\theta_{ik} - \bar{\theta}_k\right)^2}{2\sigma_k^2} \tag{27}$$

Here θ_{ik} represents the kth parameter for country i, and $\bar{\theta}_k$ is the (estimated) average across countries for the kth parameter. σ_k is the pre-specified allowable variability for the kth parameter across different countries.

In setting these factors we chose small values for factors representing biological and natural processes, while adding more room for variation when human behaviors and perceptions were involved (See Table S2 for those settings). Specifying these standard deviation priors adds a subjective element to the estimation process. We note that subjective elements are ultimately indispensable in any modeling activity: from specifying the model boundary to the level of aggregation, use of various functional forms, and choice of likelihood functions, these choices are built on subjective assessments that experts bring to a modeling project. Absent our conceptually informed variability factors, we would need to make the assumption that country-level parameters are independent, or that our complex estimation process would correctly identify the true dependencies among those parameters. We think both those alternatives are inferior in the chosen method. So here we focus on transparently documenting and explaining those assumptions, and Supplement S3 provides a validation experiment.

Table S2 summarizes the estimated model parameters, their estimated values (mean across countries and mean of Inter-Quartile Range) and the assumed variability factor (σ_k) for each.

Table S2- Estimated model parameters, their estimated values (mean and standard deviation (std) across countries and the mean of Inter-Quartile Range (MIQR). Last column reports the variability allowances used to specify the coupling among country-level estimates. See equation 27 and related discussions above.

Parameter Name		**Mean**	**StDev**	**MIQR**	**Variability Factor, σ_k**
f_b	Base Fatality Rate for Unit Acuity**	5.54E-04	5.69E-06	1.21E-05	1.00E-05
n_{ST}	Baseline Daily Fraction Susceptible Seeking Tests	7.28E-04	7.34E-04	2.89E-04	0.0005
m_T	Confirmation Impact on Contact	1.36E-01	4.91E-02	1.12E-01	0.1
α_C	Covid Acuity**	5.90E+00	1.09E-03	1.22E-02	0.01
λ	Dread Factor in Risk Perception*	4.90E+02	7.96E+02	5.01E+02	$10^{0.8}$
s_{DH}	Impact of Population Density on Hospital Availability	3.02E-01	1.14E-01	1.12E-01	0.1
s_{HF}	Impact of Treatment on Fatality Rate	3.68E-01	1.81E-01	7.60E-02	0.1
c_{Min}	Min Contact Fraction	5.37E-01	1.07E-01	8.69E-02	0.03
m_{IT}	Multiplier Recent Infections to Test	2.10E-02	1.17E-02	2.45E-02	30
m_a	Multiplier Transmission Risk for Asymptomatic**	4.79E+01	4.19E+01	1.96E+01	0.02
β	Reference Force of Infection	2.83E-01	5.46E-03	2.48E-02	0.2
T_0	Patient Zero Arrival Time	1.09E+02	2.43E+01	1.12E+01	Uniform
r_H	Reference COVID Hospitalization Fraction Confirmed	4.48E-01	1.76E-01	1.19E-01	0.1
s_f	Sensitivity of Fatality Rate to Acuity**	2.07E+00	1.84E-03	6.14E-03	0.005
s_C	Sensitivity of Contact Reduction to Utility	7.10E+00	5.81E+00	2.31E+00	6
τ_{RD}	Time to Downgrade Risk*	9.04E+01	3.13E+01	4.90E+01	$10^{0.3}$
τ_{RU}	Time to Upgrade Risk*	1.03E+01	6.80E+00	3.50E+00	$10^{0.2}$
a	Total Asymptomatic Fraction **	5.46E-01	1.47E-02	3.67E-02	0.03
w_R	Weight on Reported Probability of Infection	8.16E-01	1.37E-01	1.54E-01	0.2
s_W	Sensitivity to Weather	7.60E-01	(not applicable for global parameter)		

*Given the wide range and potential long tail for these parameters the Log10 transformation is used in specifying the dispersion penalty (equation 27) and variability factors are reported as 10^{σ}, where σ is used in equation 27.

** These parameters are expected to be less variable across countries and thus are assigned small variability allowances compared to their mean.

Excess mortality penalty

Finally, we include a likelihood-based penalty term to allow model predictions be informed by excess mortality data collected by various news agencies and researchers for a subset of countries in our sample. These data provide snapshots of excess mortality (compared to a historical baseline) for a window of time in each country. Subtracting from total excess mortality the COVID-19 deaths officially recorded in that window offers a data point for excess mortality not accounted for in official data (e_i). We can calculate in the model the counter-part for this construct: the simulated mortality that is not included in the simulated reported COVID-19 deaths ($\bar{e}_i$). There is uncertainty in these excess mortality data: the historical baselines used by various sources do not adjust for demographic change, excess mortality may be due to factors other than COVID-19, and some of it may be due to changes in healthcare availability and utilization motivated by COVID-19 but not directly attributable to the disease (for example when surgeries are delayed, hospitalization is avoided, or heart conditions are ignored). Excess mortality may also be reduced due to reduced traffic accidents (in light of physical distancing policies) and pollution related deaths. Given these uncertainties, we use the following penalty function to keep the simulated unaccounted excess mortality close to data:

$$LE = -\sum_i \left(\frac{0.9e_i - \bar{e}_i}{0.2e_i}\right)^4 \tag{28}$$

This penalty could be seen as a likelihood coming from the probability distribution $p(x) = \frac{\exp^{-x^4}}{1.8128}$ defined for all values of x. It assumes that in the most likely case for excess mortality, 90% of unaccounted mortality should be attributed to COVID-19 deaths, but that there is significant uncertainty around this, so some 20% variation across this figure is quite plausible (70%-110% of data). However, numbers outside of this range start to impose increasingly large penalties, so that very large deviation becomes unlikely.

Combining these three components, we obtain the full likelihood function used in the analysis:

$$LL = LC + LE + \sum_{t=t_0}^{t=T} LT(t) \tag{29}$$

For each country we include the LT component from the first day they have reached 0.1% of their cumulative cases to-date, or a minimum of 50 cumulative cases. This excludes very early rates that are both unreliable and which, given very small estimated model predictions for infection, could lead to unreasonably large likelihood contributions.

Numerical Methods

The model includes a large number of parameters to be estimated: a general parameter for the impact of weather, 2 general parameters for ε_j, and 20 parameters for each country that are coupled together based on the random effects framework described above. Out of those 1 parameter (per country) is for ε_i and the other 19 are informing various features of disease transmission, testing, hospitalization, and risk perception and response. With a sample of 86 countries, this would lead to 1723 parameters to be estimated. A direct optimization approach to this problem suffers from potential risk of getting stuck in local optima, and direct use of MCMC methods to find the promising regions of parameter space suffers from the curse of dimensionality. We therefore designed the following 4-step procedure

to find more reliable solutions to both problems and the synthetic data exercise in S3 provides some evidence on the effectiveness of the method.

1) We estimate the model with the full parameter vector for a smaller number of countries with larger outbreaks (3-5 countries). We use the Powell direction search method implemented in Vensim™ simulation software for this step. The method is a local search approach though it has features that allows it to escape local optima in some cases. We restart the optimization from various random points in the feasible parameter space and track the convergence of those restarts to unique local peaks. We stop this process when we are repeatedly landing on the same local peaks in the parameter space. This procedure showed that local peaks do exist, but they are not many; for example within 100 restarts we may find 2-4 distinct peaks, with one being distinctly better than others. This quasi-global peak provides a coherent set of starting points for $\boldsymbol{\phi}$ and $\overline{\boldsymbol{\theta}}$ for next steps.
2) We go through iterations of the following two steps: A) Conduct country-specific optimizations with 50 restarts to find the vector of $\boldsymbol{\theta}_i$ given the $\boldsymbol{\phi}$ and $\overline{\boldsymbol{\theta}}$ from first optimization or from the step B. B) Conduct a global optimization, including all countries but fixing $\boldsymbol{\theta}_i$ and optimizing on $\boldsymbol{\phi}$ (and $\overline{\boldsymbol{\theta}}$; though that is simply the mean across country level parameters from previous round). We stop when iterations offer little improvement from one round to the next (less than 0.05% improvement in log-likelihood).
3) We conduct a full optimization allowing all parameters ($\boldsymbol{\theta}_i$, $\boldsymbol{\phi}$ and $\overline{\boldsymbol{\theta}}$) to change, starting from the point found in the last iteration of step 2. This step finds the exact peak on the likelihood landscape which is the best-fitting parameter set for the model.
4) For the MCMC, theoretically one should conduct the sampling from all model parameters in the full model. However, our experiments showed that the large dimensionality of the parameter space requires an infeasible number of samples to achieve adequate mixing and ensure reliable credible regions for parameters and projections. To overcome this challenge we note that the parameters of different countries are connected to each other only through $\boldsymbol{\phi}$ and $\overline{\boldsymbol{\theta}}$, and these general parameters are rather insensitive to dynamics in each country. The insensitivity is due to the fact that a single country only contributes about 1% to the general parameters' values, and within a typical MCMC the country-level parameters often can't change more than 10% before the resulting samples become highly unlikely. Therefore, one can conduct an approximate country-level MCMC by fixing the general parameters at those from step 3, and only sampling from the $\boldsymbol{\theta}_i$ for each country. The MCMC algorithm used is one designed for exploring high dimensional parameter spaces using differential evolution and self-adaptive randomized subspace sampling (*11*). Using this method we obtain good mixing and stable outcomes (Robin-Brooks-Gelman PSFR convergence statistic remaining under 1.1) after about 600,000 samples (the burn-in period). We continue the MCMC for each country for another 400,000 samples and then randomly take a subsample of those points after the burn-in period for the next step.
5) The resulting subsamples for different countries from step 4 are assembled together to create a final sample of parameters for the full model to conduct projections and sensitivity analysis at the global scale. Uncertainties in the handful of global parameters is not identified in this procedure, but can be quantified by assessing the sensitivity of the global likelihood surface to changes in those parameters.

The process above is automated using a Python script that controls the simulation software (Vensim). We conduct the analysis using a parallel computing feature of Vensim on a Windows server with 48 cores. After compiling the simulation model into C++ code (which speeds up calculations significantly), and using a simulation time step of 0.25 days, it takes about 20 hours to complete the estimation for 86 countries, and a few days to complete the full suite of sensitivity analyses reported in the paper. Full analysis code is available online at https://github.com/tseyanglim/CovidGlobal.

S3 VALIDATION OF ESTIMATION FRAMEWORK

The complexity of model and the large number of parameters involved complicates the assessment of estimation method based on theoretical considerations alone. We therefore use a synthetic data experiment to build confidence in the estimation framework. Specifically, we first simulate the model using known parameters without using historical deaths and cases to provide a 'ground-truthed' set of synthetic data. We then apply the exact estimation framework used on the actual data to infer the parameters of the model from this synthetic dataset. Finally, we assess how well the estimated parameters correspond to the "true" values and how inclusive the estimated credible intervals are of the true parameters. The ability of the estimation framework to find the true parameter values, and consistent credible intervals, would increase our confidence that parameters estimated using actual data are also not particularly biased and that the credible intervals are informative. While repeating this procedure for multiple sets of synthetic data, with various parameterizations, is desirable, the computational costs in our setting make such an approach infeasible. Nevertheless, the large number of parameters estimated in a single full calibration exercise provides ample opportunities to test the precision of the method in the range of parameter values relevant in the actual data. The three steps of the process are discussed below.

Generation of synthetic data

We used the model specified above, with the parameters estimated in the baseline analysis from actual data, to generate the synthetic data. Given the deterministic nature of the model, it would be easy for the estimation process to identify the model parameters should we use the exact outcome of the baseline simulation. To test the model in a more realistic scenario, therefore, we inject two different random noise time series into the model, effectively turning the data generation simulation model into a stochastic one with underlying noise processes not accurately captured in the estimation model (because of the autocorrelation in the driving noise). Specifically, we make the following two modifications to the model equations:

$$r_{SP} = C_I W\left(\frac{S}{N}\right) N_{PI} \tag{1b}$$

Where $\frac{dN_{PI}}{dt} = \frac{N_{PI}{}^{*} - N_{PI}}{t_{Crr}}$

$$N_{PI}{}^{*} = 1 + N_G \sigma_{NI} \sqrt{\frac{2 - \frac{d_t}{t_{Crr}}}{\frac{d_t}{t_{Crr}}}}$$

And

$$f_{(.)} = f_b \alpha_{(.)}^{s_f} s_{HF}(.) g_{Ag} N_{PD} \tag{16b}$$

Where $N_{P.}$ are the noise terms changing infection and IFR rates. N_{PD} is formulated similar to N_{PI}, with parameters t_{Crr} and σ_{ND}. N_G is a standard Gaussian random number generator producing a new independent draw every time step of the simulation (d_t) for each of the two noise streams separately and independently.

These equations specify two first order autocorrelated Normally distributed noise streams. The autocorrelation time constant, t_{Cm}, is set to 10 days for both streams of noise. The σ_{NI} and σ_{ND} parameters are set to 0.15 and 0.1 (i.e. leading to standard deviation of noise around infections and deaths being 15% and 10% of the model generated baselines). As in the real world, the substantial correlation time leads to significant swings in the infection and death rates beyond those explained by model mechanisms.

To best replicate the features of actual data, the model uses actual country level data for test rates (which are exogenous inputs driving simulations) and various country level statistics such as population, population density, and age structure.

We record the data generated from this simulation for confirmed cases and deaths, corresponding to the data we have available to estimate the actual model. For each country we only record the data for the days in which we have a corresponding actual data point. We also record excess mortality counts for the subset of countries and periods for which we have such data. These three data items (two time series for confirmed infections and deaths and point estimates for excess mortalities in a subset of countries) are the inputs into the estimation process.

Estimation using synthetic data

The synthetic data generated in the previous step is available on the project's GitHub repository. This data is then used, following the estimation process discussed in S2, to find the model parameters. This step requires no other assumptions and follows the exact process used in the main analysis. Note that we start the estimation with uninformed (uniform with large ranges) priors on all parameters.

Results and comparisons

Figure S4 reports the estimated parameters, their 95% credible intervals, and the true parameters across all 1640 (86 countries x 19 parameters each) country-level parameters of the model that impact outcomes. Overall, the estimation process successfully identifies the vast majority of parameters. For example the median distance between estimated and true values, as a percentage of the length of estimated 95% credible interval, is 13%. Moreover, the credible intervals envelope the true values rather consistently. Specifically, the 50% CI includes the true value in 52% of cases and this measure increases to 68%, 77%, and 82% for 80%, 90% and 95% CIs respectively. While not identical to the expected theoretical values, these coverage levels are close, especially in the context of very large parameter spaces and complex estimation exercises where finding reliable CIs is often no easier than estimating the parameters. Overall these results add to our confidence that the estimated credible intervals are in the right range, though some may be somewhat tighter than they should be.


Base Fatality Rate for Unit Acuity (f_b)
Baseline Daily Fraction Susceptible Seeking Tests (n_{ST})
Confirmation Impact on Contact (m_T)
Covid Acuity Relative to Flu (α_C)
Dread Factor in Risk Perception (λ)
Impact of Population Density on Hospital Availability (s_{DH})
Impact of Treatment on Fatality Rate (s_{HF})
Reference COVID Hospitalization Fraction Confirmed (r_H)
Min Contact Fraction (c_{Min})
Multiplier Recent Infections to Test (m_{IT})



Figure S4-Country-level parameter estimates and 95% credible intervals from synthetic estimation exercise (blue circles and bars) compared with true values (red cross signs) across all parameters.

S4 DATA PRE-PROCESSING

Getting contemporaneous, comprehensive, national-level data on Covid-19 is a challenge. The most widely-cited data aggregators, such as the Johns Hopkins Center for Systems Science and Engineering's COVID-19 database (*12*), OurWorldInData portal (*13*), and the US-focused COVID Tracking Project (*14*), get their data from the same few official sources, such as the US Centers for Disease Control and Prevention (CDC), the European CDC (ECDC), and the World Health Organization (WHO). These official agencies in turn get their data from national and subnational public health authorities, which ultimately rely on reports from hospitals, clinics, and private and public health labs.

As a result, idiosyncrasies in the ground-level data collection processes permeate virtually all sources of aggregate data. Most notably, data collection involves time lags, which can differ from source to source. Daily death counts could reflect the date of actual death or the date a death is registered or reported; different UK government sources, for instance, use each of these metrics.[2] Daily infection or case counts could include the total new cases reported *on* a given date, or the total cases confirmed *from* that date; the latter would result in some 'backfill' whereby case counts for previous days can continue to increase for some time as delayed confirmations come in. Daily counts of tests conducted could report samples collected, samples processed, results reported, or a mix of these; the US CDC, for instance, reports a mix of testing by date of sample collection and date of sample delivery to the CDC.[3] Aside from differences in unit of measure (people vs. tests vs. samples), there may be different time lags involved as well. In addition to these idiosyncrasies, testing data in particular is also patchy for many countries, even as testing has become more widespread. The WHO does not report country-by-country testing, nor does the JHU Covid map outside the US. Furthermore, there are sometimes irregular delays in the reporting of test results, which can create occasional unexpected spikes in reported numbers of tests, infections, or both.[4]

Depending on the specifics of how daily infection and test counts are reported, there can in some cases be a disjunction between the two. Because confirmed case counts largely depend on positive test results, test and infection counts should be correlated – *ceteris paribus*, a day with a lot of samples collected for testing should see more confirmed cases attributed to it, while a day with no sample collection should see no cases. But since cases may not be reported by the date of the test, and tests may not be reported by the date of sample collection, officially reported numbers can get out of sync in either direction.

This problem is most salient when there are clear weekly cycles in daily rates. In most of the world, particularly western countries, daily test rates are far lower on weekends than during the week. As a result, infection numbers show a clear weekly cyclical component as well. But the weekly cycles in testing and infection numbers for a given country do not always line up. Our model explicitly accounts for the effect of testing on reported infections, but we do not explicitly model the country-level

---

[2] https://blog.ons.gov.uk/2020/03/31/counting-deaths-involving-the-coronavirus-covid-19/

[3] https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/previous-testing-in-us.html

[4] See e.g. https://www.wcvb.com/article/massachusetts-coronavirus-reporting-delay-due-to-quest-lab-it-glitch/32288903#

idiosyncrasies of reporting and how they vary between test data and infections. Instead we account for any such lags in pre-processing of the data to align testing and case data.

The weekly cycle occurs in many countries' death rate data as well, where it presents a different problem. A weekly cycle in testing is a behaviourally realistic part of the data-generation process, as many labs, clinics, or other testing sites for instance may be closed on weekends. As testing provides the window on the state of confirmed infections, a comparable cycle in confirmed cases is to be expected as well. By linking case confirmations to testing, our model explicitly accounts for this limited visibility on the true state of the epidemic. However, a weekly cycle in death rates almost certainly reflects different limitations of the data-generation process, typically to do with hospital staffing,[5] which we do not explicitly model. As such we need to address any weekly cycle in death rates through data pre-processing as well.

To deal with these challenges, we developed a multi-step algorithm to pre-process our data before feeding it into the model for calibration. The algorithm is described below. It was implemented in Python, largely using the Pandas and NumPy packages, and the code is available in full at: https://github.com/tseyanglim/CovidGlobal.

The algorithm proceeds country-by-country, following these steps on each country.

1) Examine daily cumulative test data; if data are insufficient (6 or fewer data points), drop country from the dataset.

2) Interpolate any missing daily cumulative test data points using a piecewise cubic Hermite interpolating polynomial (PCHIP) spline. If the first reported infection is before the first reported cumulative test, also extrapolate cumulative tests back to the date of first reported infection.
    a. Extrapolation to the date of first reported infection is necessary since both in the model and, to a large extent, in reality, reported infections require testing for confirmation.
    b. PCHIP spline interpolation yields a continuous monotonic function with a continuous first derivative, thus avoiding generating any anomalous rapid change in daily test rate.
    c. We used the implementation of PCHIP interpolation from the widely used SciPy package for Python.[6]

3) Calculate daily test rate as daily cumulative tests less the preceding day's cumulative test total:

---

[5] It may be argued that there are weekly cycles in large-scale human behaviour that may drive some true weekly cyclicality in the true rates of infection and death, and as such it may be wrong to consider such cycles to be artefacts of the data-generation process. However, we find this unlikely for a few reasons. First, weekly cycles in human interactions, largely driven by the work and school week and weekend, will have been significantly attenuated by widespread adoption of social distancing measures around the world. Second and more importantly, variation in incubation period and time before development of symptoms means that any true cyclicality in the timing of initial infection will be further attenuated in the timing of symptom development. By the same logic, wide variability in the delay from symptom development to death means there should be minimal cyclicality, if any, in the timing of deaths, meaning any such cycles visible in the data are due to measurement and reporting lags.

[6] https://docs.scipy.org/doc/scipy/reference/generated/scipy.interpolate.PchipInterpolator.html

$$TestRate_t = CmltTest_t - CmltTest_{t-1} \quad (30)$$

4) Examine the original daily cumulative test data to estimate how much of the calculated daily test rate is based on interpolated vs. original data.
    a. Daily test rates calculated based on mostly original data should be expected to include any weekly cycles or occasional irregularities that would also be reflected in daily infection counts. Conversely, daily test rates calculated from cumulative test counts that are largely interpolated would not be expected to fully reproduce any such cycles or irregularities, since the interpolation produces a relatively smooth function.
    b. As a rule of thumb, we examine the cumulative test data for the second half of the time from the first test to the latest test. If fewer than half the days in that window have original cumulative test data, we consider the test data to be 'sparse', requiring further processing.

5) If the test data are not sparse, account for any potential lag or other reporting delay differences between daily test rate and daily infection rate using a time-shift algorithm to estimate any such lags or delays from the data and shift the test rate time series accordingly. The time-shift algorithm ensures that any weekly cycles present in the daily infection rate data are reflected in the daily test rate data and aligned as best as possible on date, thereby accounting for the fact that model-generated reported infections depends on testing but with no time lag between test and result.
    a. First, identify the weekly component of the time series of daily infection rate and daily test rate using a seasonal-trend decomposition based on LOESS (STL) procedure.[7]
        i. STL deconstructs time series data into several components, including a trend and a seasonal component over a specified period (weekly, in this case) as well as a residual. STL is an additive decomposition, and has the advantage of allowing the seasonal component to change over time (rather than being a fixed pattern repeated exactly across the whole time series).
        ii. We used the STL implementation from the Statsmodels package for Python.[8]
    b. Shift the time series over a one-week range (from -2 to +4 days of lag between test and infection reporting), calculating the cross-correlation between the weekly seasonal component of the daily infection rate data and the daily test rate data for each time shift.
    c. Identify the time shift within this range that maximizes the cross-correlation between the infection rate and test rate data, and shift the test rate data accordingly.

6) If the test data are sparse, the spline interpolation will generally cut out some of any weekly cyclicality that may be present. Visual inspection of daily test rates for countries with sparse test data also shows large, irregular spikes in reported tests are not uncommon, without necessarily having concomitant irregular spikes in reported daily infection rates. As such, rather than attempting to eliminate differences in reporting lags through the time-shift algorithm described above, we instead apply a data-smoothing algorithm to both daily test rate and daily infection rate,

---

[7] Cleveland R.B., Cleveland W.S., McRae J.E., Terpenning I. (1990) STL: A seasonal-trend decomposition procedure based on Loess. *J Off Stat* 6: 3-73

[8] https://www.statsmodels.org/stable/generated/statsmodels.tsa.seasonal.STL.html

in order to reduce any cyclicality and irregular spikes. This smoothing allows the calibration of the main model to focus on matching the underlying trends in the data.

7) In all cases, whether daily cumulative test data are sparse or not and whether infection and test rate data are smoothed or not, since weekly cycles in death data are reflective of reporting lags not captured in the model, daily death rate data is smoothed using the same algorithm.

8) The smoothing algorithm used is designed first to conserve the total number of reported cases (tests, infections, or deaths), and second to preserve some degree of variation in the time series, as some noise may be informative and retaining some is important to the calibration of the model.
   a. Starting from when the time series of daily rate (test or infection) exceeds a specified minimum value (5/day), calculate the rolling mean of the daily rate, using a centred moving window of 11 days.
   b. Calculate the residual between each day's data point and the rolling mean for that day, and divide by the square root of the rolling mean, to get an adjusted deviation value:

$$AdjDev_t = \frac{Value_t - RollMean_t}{\sqrt{RollMean_t}} \tag{31}$$

      i. Dividing by the square root of the rolling mean reflects a heuristic assumption that each daily rate (of infections, deaths, or tests) behaves as a Poisson process (StDev of Pois(λ) = $\lambda^{0.5}$).
      ii. The functional result of this adjustment is that both *absolute* and *relative* magnitudes of deviations from the rolling mean are given some weight – large relative deviations when absolute values are small (and data are noisier) are not ignored, but neither do they outweigh larger absolute (but smaller relative) deviations that occur when the mean is large, which is important since most of the time series data are growing significantly over the time horizon of the model.
   c. Calculate thresholds for identifying dips and peaks in the data based on the median of the adjusted deviations, ± one median absolute deviation (MAD) of the adjusted deviations:

$$Threshold = \widetilde{AdjDev} \pm Med\left(\left|AdjDev_i - \widetilde{AdjDev}\right|\right) \tag{32}$$

      i. Using the median absolute deviation to determine thresholds for peaks and dips is robust to outliers in the deviations, which do arise occasionally in the data.
      ii. A threshold width of one MAD is relatively narrow for outlier detection, but by inspection of the data, is about right for identifying most of the peaks and dips caused by weekly cycles in test, infection, and death rates, as well as larger outliers.
   d. Once thresholds are calculated, iterate through the data points in the time series first forward in time from oldest to newest, filling in any 'dips' (data points with adjusted deviations below the lower threshold), then backward in time from newest to oldest, smoothing out any 'peaks' (data points with adjusted deviations above the upper threshold) that remain. Repeat the process until all data points' adjusted deviations are within the originally calculated thresholds for the time series.

i. We infer that the underlying processes generating dips and peaks are somewhat different. Dips are generally the result of weekly cycles in the data, e.g. lower rates of testing or longer lags in death reporting that occur on weekends. Peaks arise to some extent due to the same weekly processes, e.g. some deaths that occur on weekends only being recorded at the start of the next week. However, some peaks, especially larger ones, may result from irregular random delays in reporting, such as large batches of tests being held up due to logistical issues and then getting processed all at once. As such the smoothing procedure for dips vs. peaks is slightly different.

e. The dip-filling step fills a fraction of each dip (specified as a *smoothing factor*) by redistributing data counts based on a multinomial draw from the subsequent few days following each dip.
   i. First, calculate the amount to fill based on the deviation and the smoothing factor specified, in this case 0.67:

$$FillAmt_t = SmFactor \times (RollMean_t - Value_t) \tag{32}$$

   ii. Calculate the amount redistributed from each of the following few (7) days $X_{t+1}, X_{t+2}, \dots X_{t+k}, k = 7$, based on a multinomial distribution as follows:

$$X_{t+1}, X_{t+2}, \dots X_{t+7} = Multinomial(FillAmt_t; p_{t+1}, p_{t+2}, \dots\ p_{t+7}) \tag{33}$$

Where $p_{t+1}, p_{t+2}, \dots\ p_{t+7}$ are calculated as:

$$p_{t+i} = \frac{AdjDev_{t+i} - AdjDev_t, min.0}{\sum_1^7 (AdjDev_{t+i} - AdjDev_t, min.0)} \tag{34}$$

   iii. This formulation allows some redistribution from any of the subsequent few days whose adjusted deviations exceed the focal day's adjusted deviation, but with more redistribution from days with higher adjusted deviations.

f. The peak-smoothing step similarly redistributes a fraction of each peak, specified by the smoothing factor, to the *preceding* several days based on another multinomial draw.
   i. First, calculate the amount to redistribute similarly to the dip-filling step:

$$DistAmt_t = SmFactor \times (Value_t - RollMean_t) \tag{35}$$

   ii. Calculate the amount redistributed *to* each of the preceding several (14) days $Y_{t-1}, Y_{t-2}, \dots Y_{t-k}, k = 14$, based on a multinomial distribution as follows:

$$Y_{t-1}, Y_{t-2}, \dots Y_{t-14} = Multinomial(DistAmt_t; p_{t-1}, p_{t-2}, \dots\ p_{t-14}) \tag{36}$$

Where $p_{t-1}, p_{t-2}, \dots\ p_{t-14}$ are calculated as:

$$p_{t-i} = \frac{RollMean_{t-i}}{\sum_1^{14} RollMean_{t-i}} \quad (37)$$

iii. This formulation redistributes peaks to preceding days based on the calculated rolling mean counts of those days, on the assumption that the irregular delays that generate random spikes in counts are essentially random and equally likely to affect any given unit of data over a several-day span. As such, the probability that a unit showing up in a spike due to such delays comes from a given preceding day is simply proportional to the expected count for that day, as approximated by the rolling mean.

g. By filling dips first before smoothing peaks, the combined algorithm largely addresses any peaks that are due primarily to weekly cycles during the dip-filling stage, such that remaining peaks that get smoothed tend to be the larger, irregular ones.

S5 EXTENDED RESULTS

Quality of fit measures

Table S3 reports two quality of fit metrics for different countries and different time series. The first four columns report Mean Absolute Error Normalized by Mean (MAEN) and the last four report the R-Squared measures. Errors for cumulative infection and deaths are followed by those for the new cases and deaths (flow variables).

Table S3- Measures of fit between data and simulations for different countries. Mean Absolute Error Normalized by Mean (MAEN) and R-Squared are reported for cumulative and new cases and deaths.

	MAEN				**R-Squared**			
	Cumulative		**Flow**		**Cumulative**		**Flow**	
Country	**Infection**	**Death**	**Infection**	**Death**	**Infection**	**Death**	**Infection**	**Death**
Albania	0.132	0.3	0.401	0.928	0.961	0.859	0.753	0.261
Argentina	0.159	0.0602	0.29	0.175	0.982	0.998	0.954	0.917
Armenia	0.0612	0.119	0.139	0.28	0.999	0.994	0.945	0.828
Australia	0.0693	0.0373	0.324	0.924	0.99	0.993	0.825	0.367
Austria	0.0583	0.0597	0.416	0.341	0.985	0.997	0.638	0.852
Azerbaijan	0.0676	0.157	0.162	0.323	0.997	0.997	0.951	0.83
Bahrain	0.101	0.149	0.237	0.783	0.999	0.979	0.842	0.413
Bangladesh	0.0777	0.093	0.138	0.241	0.999	0.996	0.921	0.782
Belarus	0.077	0.0894	0.15	0.276	0.999	0.994	0.913	0.622
Belgium	0.256	0.511	0.429	0.514	0.993	0.976	0.763	0.904
Bolivia	0.0504	0.0631	0.224	0.162	1	0.998	0.879	0.949
Bosnia	0.777	0.0857	0.883	0.737	0.852	0.972	0.0637	0.0811
Bulgaria	0.141	0.245	0.47	0.624	0.973	0.985	0.571	0.17
Canada	0.623	0.151	0.65	0.185	0.997	0.999	0.775	0.892
Chile	0.333	0.155	0.426	0.605	0.986	0.97	0.262	0.516
Colombia	0.125	0.0778	0.403	0.221	0.984	0.993	0.727	0.947
CostaRica	0.306	0.45	0.631	1.46	0.856	0.886	0.707	0.15
Croatia	0.365	0.0736	0.535	0.853	0.946	0.985	0.511	0.223
Cuba	0.0543	0.14	0.33	0.863	0.998	0.955	0.689	0.471
Cyprus	0.014	0.22	0.166	1.52	0.999	0.899	0.964	0.0394
CzechRepublic	0.173	0.122	0.374	0.39	0.988	0.992	0.625	0.784
Denmark	0.201	0.0396	0.37	0.319	0.998	0.998	0.803	0.799
Ecuador	0.172	0.0539	0.71	0.38	0.986	0.992	0.0619	0.545
ElSalvador	0.0538	0.18	0.21	0.466	0.995	0.995	0.908	0.72
Estonia	0.0878	0.0562	0.523	1.04	0.998	0.991	0.615	0.296
Ethiopia	0.128	0.182	0.568	0.99	0.991	0.974	0.341	0.188
Finland	0.325	0.0624	0.514	0.322	0.996	1	0.657	0.871
France	0.118	0.393	0.318	0.396	0.993	0.988	0.853	0.933
Germany	0.0582	0.0201	0.252	0.132	0.989	1	0.893	0.967
Ghana	0.068	0.198	0.58	1.28	0.995	0.984	0.421	0.101
Greece	0.144	0.0874	0.536	0.674	0.995	0.997	0.398	0.424
Hungary	0.176	0.104	0.414	0.254	0.999	0.998	0.628	0.845
Iceland	0.0716	0.457	0.326	1.99	0.998	0.93	0.846	0.0336
India	0.0882	0.0849	0.174	0.24	0.994	0.994	0.979	0.839
Indonesia	0.172	0.0387	0.302	0.165	0.996	0.999	0.702	0.863
Iran	0.0511	0.0553	0.172	0.194	0.998	0.993	0.646	0.646
Ireland	0.0767	0.0268	0.378	0.189	0.996	0.999	0.745	0.944
Israel	0.29	0.0358	0.495	0.353	0.932	0.998	0.419	0.756
Italy	0.0307	0.0261	0.162	0.133	0.997	0.999	0.944	0.963
Japan	0.672	0.0939	0.873	0.371	0.992	0.991	0.451	0.728
Kazakhstan	0.202	0.206	0.697	0.898	0.928	0.962	0.142	0.165
Kenya	0.0955	0.277	0.364	0.675	0.988	0.981	0.684	0.272
Kuwait	0.0377	0.178	0.171	0.346	0.998	0.983	0.903	0.712
Kyrgyzstan	0.204	0.192	0.461	0.673	0.94	0.968	0.846	0.64
Latvia	0.0483	0.133	0.481	1.55	0.997	0.976	0.567	0.0299
Lithuania	0.038	0.0768	0.447	1.01	0.997	0.993	0.601	0.146
Luxembourg	0.0643	0.0312	0.384	0.905	0.995	0.994	0.768	0.358

Malaysia	0.321	0.0544	0.706	0.702	0.988	0.99	0.339	0.499
Maldives	0.0299	0.222	0.485	1.77	0.996	0.94	0.109	0.000719
Mexico	0.0525	0.0606	0.261	0.162	0.998	0.999	0.741	0.897
Morocco	0.0756	0.0567	0.367	0.453	0.992	0.986	0.403	0.559
Nepal	0.172	0.264	0.32	1.12	0.998	0.92	0.767	0.106
Netherlands	0.0433	0.0546	0.12	0.154	1	0.998	0.971	0.957
NewZealand	0.0633	0.13	0.251	1.52	0.995	0.96	0.928	0.164
Nigeria	0.062	0.0988	0.375	0.305	0.996	0.993	0.461	0.654
NorthMacedonia	0.0967	0.0808	0.31	0.461	0.982	0.989	0.835	0.517
Norway	0.0913	0.0252	0.383	0.466	0.997	0.998	0.742	0.783
Pakistan	0.13	0.0716	0.389	0.302	0.987	0.993	0.596	0.716
Panama	0.0898	0.148	0.372	0.396	0.984	0.975	0.681	0.572
Paraguay	0.11	0.326	0.686	1.58	0.971	0.851	0.265	0.0443
Peru	0.457	0.0961	0.556	0.144	0.993	1	0.183	0.984
Philippines	0.138	0.0515	0.422	0.292	0.976	0.997	0.67	0.447
Poland	0.0559	0.0631	0.238	0.244	0.997	0.999	0.391	0.638
Portugal	0.0791	0.031	0.286	0.21	0.994	0.999	0.536	0.889
Qatar	0.373	0.559	0.411	0.803	0.988	0.989	0.612	0.467
Romania	0.137	0.0603	0.269	0.229	0.996	0.998	0.467	0.661
Russia	0.0688	0.0263	0.0807	0.115	0.998	0.999	0.925	0.942
Rwanda	0.149	0.437	0.596	1.9	0.962	0.89	0.378	0.034
SaudiArabia	0.0551	0.0854	0.237	0.231	0.996	0.995	0.814	0.876
Senegal	0.0369	0.115	0.236	0.643	0.999	0.986	0.741	0.477
Serbia	0.0838	0.161	0.272	0.491	0.997	0.981	0.755	0.295
Singapore	0.155	2.98	0.171	5.61	0.998	0.848	0.927	0.0158
Slovakia	0.188	0.116	0.683	1.35	0.993	0.956	0.409	0.34
Slovenia	0.164	0.0929	0.45	0.724	0.993	0.995	0.699	0.541
SouthAfrica	0.132	0.092	0.283	0.185	0.983	0.996	0.93	0.93
SouthKorea	0.0706	0.122	0.362	0.555	0.988	0.992	0.804	0.511
Spain	0.125	0.045	0.408	0.215	0.971	0.998	0.774	0.939
Sweden	0.142	0.135	0.344	0.273	0.973	0.996	0.369	0.787
Switzerland	0.212	0.394	0.302	0.436	0.998	0.992	0.877	0.898
Thailand	0.0162	0.94	0.389	1.28	0.996	0.991	0.766	0.632
Tunisia	0.354	0.213	0.692	1.05	0.991	0.984	0.542	0.341
Turkey	0.00889	0.0342	0.149	0.117	1	0.999	0.906	0.957
UAE	0.0229	0.279	0.142	0.662	0.999	0.916	0.887	0.233
UK	0.36	0.127	0.503	0.164	0.991	0.999	0.751	0.933
Ukraine	0.0439	0.108	0.21	0.194	0.995	0.994	0.727	0.747
USA	0.0631	0.0353	0.231	0.112	0.991	1	0.412	0.928

Figure S5 shows the visualization of fit between data and simulations for all the countries in our sample. These graphs include data and model outputs for reported new cases (blue; left axis in thousands per day) and deaths (red; right axis in thousands per day) starting from the beginning of the epidemic in each country until 10 July 2020.



Figure S5- Comparison of data and simulation. New cases in blue (left axis, in thousands per day) and new deaths (red, right axis).

Estimates for true magnitude of epidemic

Estimates for true cumulative cases (blue; left axis in millions) and deaths (red; right axis in thousands) across different countries up to 10 July 2020 are reported in Figure S6.



Figure S6- Estimates and 95% credible intervals for true magnitude of epidemic. Cumulative cases (blue, left axis in millions) and cumulative deaths (red, right axis, in thousands)

Excess deaths

Figure S7 shows the ratio of estimated excess deaths, i.e. COVID-19 fatalities not reported as such, to reported excess deaths, i.e. deaths over historical baseline not accounted for by reported COVID-19 deaths, for the countries for which such data are available.



Figure S7- Ratio of estimated excess deaths to reported excess deaths.

Maximum reproduction number

Figure S8 shows the initial reproduction number (R_E) occurring in each country. Reproduction numbers are changing dynamically and transient dynamics may lead to larger than equilibrium numbers if maximum R_E values were used. We therefore use the 90th percentile of simulated reproduction number in this graph. Also note the large credible intervals for these estimates. This range is partly driven by what exact point of the curve is represented by the 90th percentile. It is also due to the inherent uncertainty when both reproduction number and behavioral and policy responses are estimated: one can have smaller initial R_E and smaller response functions, or larger values for both, and stay consistent with the data, specially because early in the epidemic ascertainment rates are very low and data is not very informative about the true magnitude. Moreover, given the recording of R_E values at their (often initial) high values, they may reflect non-representative subpopulations or events. For example the large maximum R_E value estimated for Iran may be partially explained by the fact that the start of epidemic in the country coincided with the major official ceremonies and rallies at the anniversary of 1979 revolution. Those rallies probably seeded the epidemic in thousands people, and are picked up by the model to inform the maximum R_E.



Figure S8- Maximum reproduction number R_E for each country's outbreak

Time to herd immunity

Figure S9 shows estimated time to herd immunity across nations. These estimates are based on time it takes before 80% of population has been infected by COVID-19. Depending on the basic reproduction number in each location the 80% threshold may be on the larger side for some countries, but offers a reasonable intuition for the ranges of time involved and could be adjusted with a linear scaling to other thresholds. Two estimates are offered, one for the estimated number based on current true infection rates, and another based on the peak infection rates experienced in that country. The two may be the same if the current rates are the peak rates.



Figure S9- Time to 80% cumulative infection based on current infection rates (blue circles) and peak infection rates to-date (red squares) in days (log scale).

Parameter estimates

Figure S10 reports most likely estimates for the vector of country-specific parameters ($\boldsymbol{\theta}_i$). The figure also includes 95% credible intervals for these parameter estimates.


Base Fatality Rate for Unit Acuity (f_b)
Baseline Daily Fraction Susceptible Seeking Tests (n_{ST})
Confirmation Impact on Contact (m_T)
Covid Acuity Relative to Flu (α_C)
Dread Factor in Risk Perception (λ)
Impact of Population Density on Hospital Availability (s_{DH})
Impact of Treatment on Fatality Rate (s_{HF})
Reference COVID Hospitalization Fraction Confirmed (r_H)
Min Contact Fraction (c_{Min})
Multiplier Recent Infections to Test (m_{IT})



Figure S10- Parameter estimates and 95% credible regions for country-specific parameters.

Future projections

Figure S11 reports country-level projections for new cases and deaths based on the scenario I (no changes in estimated parameters; testing fixed at values observed for July 10, 2020; consistent with those reported in Figure 6-B and 6-C in the main paper). Note that in scenario III in the main paper (not shown here) we shift contact sensitivity to perceived risks (s_C) to represent some improvement in behavioral and policy responses to infection risk, without completely changing how each country behaves. Specifically, on 16 July 2020 we shift s_C to a value 20% between the one estimated for the country and 8 (which strengthens response in most countries and weakens it in a few).



Figure S11- Country level projections until Spring 2021 in scenario I. Daily cases (in thousands, blue, left axis) and daily deaths (red, right axis) are graphed.

S6 OUT OF SAMPLE PREDICTION TEST

We conducted an out of sample prediction test of the model by comparing the quality of fit for model projections for future data not used in model estimation against the version of the model using that data. For the baseline prediction we used the analysis in the first version of this manuscript, which was released publicly on June 24, 2020, using data until June 16th. We calculate the quality of fit for projections of that model (call it the "early model") for data later released for the period June 17-July 10. Those projections are reported in Figure S12 and are directly comparable with Figure S5. Inspection of this graph points to various outcomes across countries, ranging from close fit for the prediction interval to major discrepancies. For example, the model was able to predict the emergence of a second wave, before it was detectable in the infection data, across Australia, Czech Republic, Greece, Luxembourg, Morocco, and Serbia.

The discrepancies arise from both the baseline gaps between the model and data and emerging features of the epidemic in the prediction interval. The baseline gaps typically appear because our method enforces a strong coupling among countries. For instance, keeping IFR parameters similar across countries, the model cannot explain the unexpectedly low fatality rates in Qatar and Singapore. Another potential sources of mismatches is the heterogeneity in some countries not reflected in our model. For example, the "second wave" in the USA is largely due to the rise of cases in a number of states which did not have as large an outbreak earlier. Combining all those states into a single mixed set of compartments our model fails to identify the wave earlier. The increased gaps in the prediction interval results from both divergence in testing (the early model uses test rates in the final day, June 16th, for the rest of the simulation, creating significant errors in some cases, e.g. Mexico) as well as model's failure to accommodate changes in responses that are not detectable in the historical data (e.g. missing the magnitude of the "second wave" in Israel). If we remove the first contributing factor by using the true test rates for the prediction period but not using the data from that period for estimation, the quality of fit relative to the model using the full data improves (from 0.68 to 0.81; see Table S4).



Figure S12-Predictions from the June 16th model for June 17-July 10 interval. The start of prediction interval is marked with a horizonal blue line. Cyprus and Senegal were not in the early model sample, but are present in the current version (thus their graphs are missing).

While nobody expects a model to offer a perfect fit, assessing the quality of fit requires some benchmark to compare against. Defining external benchmarks in the case of current model is complicated because no other model has attempted to simultaneously match infection and fatality data across this large set of nations. Therefore, we focus on an internal benchmark using quality of fit for the version of the model using the data from the prediction interval for estimation. Specifically, we compare the fit measures from the early model (MAEN scores for reported infection rates and death rates) against the same fit measures coming from the version of the model reported in the current (updated) paper. The updated version uses the data between June 17 and July 10th, thus is likely to have a better fit than the early version of the model. The ratio of MAEN values between these two models informs the speed with which fit quality deteriorates, with values closer to one suggesting robust long-term predictions. Table S4 reports those values across different nations. We also conduct

the same exercise, but using the actual test data for the prediction period, finding an improved fit ratio measure of 0.81 averaged across all nations.

Table S4- Quality of fit for future projections compared to when data is available. Mean Absolute Error Normalized by Mean (MAEN) for daily infection rates in the early model, current model (which uses data from prediction interval of June 17-July 10), and the ratio of current model's MAEN to the early one. Note that a few countries (Cyprus, Rwanda) are included in the current model but did not meet the inclusion threshold at the time of the early model.

Mean fit ratio: 0.684

Infection MAEN between days 248 and 270 for different countries:							
Country	**Current**	**Early**	**Ratio**	**Country**	**Current**	**Early**	**Ratio**
Albania	0.347	0.699	0.496	Kyrgyzstan	0.398	0.795	0.501
Argentina	0.309	0.597	0.517	Latvia	0.929	0.944	0.985
Armenia	0.0857	0.822	0.104	Lithuania	0.574	1.63	0.351
Australia	0.372	0.75	0.496	Luxembourg	0.335	0.624	0.536
Austria	0.262	0.275	0.952	Malaysia	0.619	6.24	0.0992
Azerbaijan	0.125	0.182	0.687	Maldives	0.392	0.516	0.759
Bahrain	0.154	0.179	0.864	Mexico	0.271	0.336	0.807
Bangladesh	0.109	0.271	0.4	Morocco	0.36	0.539	0.668
Belarus	0.324	1.05	0.307	Nepal	0.35	0.542	0.645
Belgium	0.464	0.476	0.974	Netherlands	0.183	1.29	0.142
Bolivia	0.188	0.398	0.473	NewZealand	0.6	0.768	0.781
Bosnia	0.736	0.937	0.785	Nigeria	0.357	0.219	1.63
Bulgaria	0.402	0.642	0.626	NorthMacedonia	0.19	0.343	0.556
Canada	0.244	0.261	0.936	Norway	0.625	1.2	0.521
Chile	0.269	0.364	0.74	Pakistan	0.267	0.293	0.914
Colombia	0.411	0.659	0.624	Panama	0.292	0.577	0.507
CostaRica	0.556	0.876	0.635	Paraguay	0.527	0.773	0.681
Croatia	0.383	0.966	0.397	Peru	0.385	0.449	0.856
Cuba	0.6	2.11	0.284	Philippines	0.359	0.551	0.652
Cyprus	0.492	NaN	NaN	Poland	0.252	0.343	0.735
CzechRepublic	0.399	0.415	0.963	Portugal	0.163	0.177	0.921
Denmark	0.825	1.28	0.643	Qatar	0.283	0.488	0.581
Ecuador	0.587	0.706	0.831	Romania	0.255	0.411	0.619
ElSalvador	0.156	0.427	0.365	Russia	0.0508	0.0937	0.542
Estonia	1.11	4.12	0.27	Rwanda	0.495	NaN	NaN
Ethiopia	0.803	0.851	0.943	SaudiArabia	0.225	0.322	0.7
Finland	0.551	0.594	0.927	Senegal	0.153	0.179	0.858
France	0.334	0.305	1.1	Serbia	0.21	0.609	0.345
Germany	0.26	0.367	0.71	Singapore	0.119	0.554	0.215
Ghana	0.42	0.462	0.909	Slovakia	0.548	0.826	0.663
Greece	0.305	0.439	0.695	Slovenia	0.365	0.744	0.491
Hungary	0.52	0.445	1.17	SouthAfrica	0.297	0.626	0.475

Iceland	0.479	0.517	0.926	SouthKorea	0.273	0.23	1.19
India	0.177	0.224	0.79	Spain	0.327	0.529	0.619
Indonesia	0.183	0.214	0.857	Sweden	0.39	0.37	1.05
Iran	0.0599	0.178	0.336	Switzerland	0.419	0.518	0.808
Ireland	0.506	0.536	0.943	Thailand	0.787	0.853	0.923
Israel	0.388	0.886	0.438	Tunisia	0.656	1.06	0.619
Italy	0.275	0.826	0.333	Turkey	0.138	0.0942	1.46
Japan	0.525	0.735	0.715	UAE	0.173	0.276	0.626
Kazakhstan	0.697	0.793	0.879	UK	0.278	0.354	0.785
Kenya	0.405	0.469	0.865	Ukraine	0.21	0.349	0.601
Kuwait	0.184	0.366	0.501	USA	0.365	0.574	0.635

S7 SENSITIVITY ANALYSIS

Impact of Cross-country Parameter Variances

Setup- Our estimation method uses a random effects framework, which couples the parameters across different countries, specifying them as instances of some underlying distribution with a given variance. Those variance factors, explained in S2, were specified to incorporate the authors' judgement on how different each parameter may be across different countries, based on the nature of those parameters. For instance, parameters representing physiological or virological constructs should generally vary less than those representing socio-cultural and behavioral responses. In principle, one could propose other variance factors. Assuming very large variances would essentially decouple the models for different countries, while shrinking variances towards zero will force all parameters to be the same across countries. In this section we assess the sensitivity of results to changes in those variance factors. Specifically, we re-do the analysis when all variance factors are scaled by a factor of 4, or 0.25. We re-estimate the model in each case and measure how much the following 12 outcome measures (organized into 3 groups) change compared to the baseline estimates as a result:

a) Country level projections for 1) Actual to reported case ratio; 2) Actual to reported death ratio; 3) Projected infection rate at the end of Winter 2021; 4) Projected death rate at the end of winter 2021;
b) Country level MAEN values for daily infection rates and death rates;
c) Aggregate (across all countries) cumulative infections, deaths, and IFR, both on 10 July 2020 and at the end of Winter 2021.

The first two groups of measures are country specific, so we report them for all countries, followed by their averages, and then the aggregate outcomes.

Results- In

Table S5 and

Table S6 results from these two experiments are reported. As expected, increasing allowed variances enables the model to offer a better fit to data (i.e. reduces MAEN values, thus negative values for fit statistics in the second experiment). Other sensitivities remain relatively small, showing few systematic changes in model's predictions as in response to changes in the cross-country parameter variances.

Table S5- Impact of decreasing assumed cross-country parameter variances by a factor of four. All reported outcomes measure percentage change in the given metric from baseline analysis.

Sensitivities to 4x change in variances						
Country	**Case Undercount Ratio**	**Death Undercount Ratio**	**Final Infection Rate**	**Final Death Rate**	**MAEN Infection**	**MAEN Death**
Albania	11.8	0.853	-29.4	-23.8	-1.81	-1.77
Argentina	-6.79	-0.196	36.5	35.8	-6.82	-0.667
Armenia	0.178	1.48	4.17	3.1	-0.472	-1.92
Australia	20.1	1.48	4.02	-21.6	-2.19	-1.35
Austria	4.18	-0.523	-0.499	-3.36	-0.422	-4.26
Azerbaijan	-2.42	6.52	15.5	20.9	2.58	-3.94
Bahrain	2.46	-4.76	-2.83	-11.9	1.09	-2.08
Bangladesh	-0.637	0.0198	3.03	3.11	0.242	-0.781
Belarus	2.64	-0.784	-7.61	-7.38	-4.82	-3.4
Belgium	-1.9	1.46	0.0173	3.79	-3	-1.75
Bolivia	-4.26	-1.62	16.3	18.9	-0.461	-1.64
Bosnia	-6.72	3.8	-3.71	6.82	-3.94	-0.0534
Bulgaria	-4.74	7.32	3.77	13.6	-0.703	0.942
Canada	-0.0894	0.0123	0.943	1	-0.557	0.278
Chile	-2.88	-8.9	44.5	39	-6.13	-8.13
Colombia	11.5	6.32	-23.5	-24.9	1.01	-6.45
CostaRica	13.9	-8.47	38.7	42.3	-2.05	-4.6
Croatia	-2.95	0.575	-94.9	59.9	-9.65	-1
Cuba	3.08	-5.3	1.48	-12.1	-0.968	-5.04
Cyprus	-0.233	2.73	0.251	2.27	-0.00704	0.298
CzechRepublic	3.68	0.34	1.13	-2.11	0.313	-1.84
Denmark	-10.3	-1.34	-5.87	-4.22	-12.5	-17.3
Ecuador	5.05	2.34	15	14	-0.0741	-0.923
ElSalvador	1.28	3.91	-29.3	-22.8	-0.483	-0.422
Estonia	22.3	1.49	31.7	10.4	-1.38	-2.01
Ethiopia	25	17.2	-2.35	2.81	-0.206	-0.482
Finland	-2.24	-0.465	-21.3	-19.4	-15.1	-3.12
France	2.48	6.25	3.34	9.1	-0.177	-13
Germany	6.95	2.94	1.01	-2.2	-2.34	-0.279
Ghana	-3.16	3.54	-9.16	-5.75	-1.13	0.906
Greece	-4.65	0.962	-1.05	6.07	-1.91	0.178
Hungary	-13.7	-0.179	-9.21	7.68	-9.68	0.571
Iceland	3.23	-19.7	-14.2	-33.1	0.661	-10.4
India	-7.06	-0.161	5.17	10.9	8.66	3.14
Indonesia	-0.118	-0.148	-0.0355	-0.0596	-0.195	-0.0252
Iran	3.24	3	1.74	2.54	4.15	-2.68
Ireland	-0.246	1.14	-2.09	1.56	-1.56	0.383
Israel	6.48	-1.15	-18.1	-8.76	0.423	0.19
Italy	-0.707	0.806	0.669	2.94	-4.14	1.71
Japan	11.3	13.8	-5.38	-3.99	-10.2	-6.16
Kazakhstan	3.34	-1.26	-5.84	-16.1	0.384	-0.454
Kenya	-9.36	-2.21	4.65	0.877	-1.08	1.37
Kuwait	-1.23	1.04	0.604	2.67	-0.652	0.217
Kyrgyzstan	24.4	11.1	-41.4	-49.6	0.43	-3.41
Latvia	-33.6	-40.8	-15.9	-22.7	17.9	-14.2
Lithuania	-0.516	3.11	0.101	4.02	-0.642	0.713
Luxembourg	5.49	-1.62	28.9	-14	0.808	-1.37
Malaysia	13.7	8.6	-2.05	-23.4	-0.675	-4.02

Maldives	1.23	-4.89	-3.66	-10	-0.144	-2.13
Mexico	-9.63	-11.7	12.1	-0.336	-4.42	1.24
Morocco	-1.34	-2.96	-1.44	-4.19	0.067	-2.29
Nepal	4.5	-13.9	-4.56	-24.5	-9.47	-6.89
Netherlands	-1.65	0.393	2.2	0.55	-8.02	-0.397
NewZealand	2.09	-7.69	-33.3	-3.14	-1.74	-2.59
Nigeria	-18	-16.4	5.29	0.305	-2.02	-3.09
NorthMacedonia	2.38	0.381	-5.19	-5.62	-0.641	-0.347
Norway	2.27	-0.446	-1.15	-4.24	1.1	-2.06
Pakistan	20.7	13.1	-4.45	-8.62	0.587	-0.73
Panama	2.89	-0.729	6.76	-0.842	-2.96	-1.64
Paraguay	3.06	-10.5	47.6	72.7	-1.03	-4.34
Peru	4.23	-0.141	-8.55	-25.9	-0.031	-24.1
Philippines	-3.86	-1.97	5.82	-0.008	-5.98	-1.58
Poland	-0.937	0.805	-2.16	-0.803	-2.08	0.0773
Portugal	6.12	2.04	6.13	-1.64	2.56	-8.58
Qatar	-0.0347	-3.18	-1.04	-8.52	-5.29	-2.48
Romania	-4.57	0.354	2.73	10.6	-3.4	-4.28
Russia	0.187	-0.286	-5.09	-4.58	-0.253	-0.363
Rwanda	2.09	-11.3	59.1	59	-0.747	-5.2
SaudiArabia	-1.35	1.96	-2.07	2.22	-0.135	-2.23
Senegal	5.25	0.245	62.9	61.2	-0.127	-1.36
Serbia	-2.18	-4.47	7.16	1.45	-2.39	-2.94
Singapore	3.96	-15.5	-0.465	-18.8	-8.19	-14.6
Slovakia	4.26	-8.71	29.4	-12.1	1.41	-4.36
Slovenia	6.27	5.73	-33.6	-13.9	-5.64	-0.953
SouthAfrica	-6.19	-0.034	123	119	-15.6	-11.9
SouthKorea	8.6	2.68	23.4	19.4	0.322	-4.57
Spain	-1.63	0.813	3.23	10.6	-2.95	0.229
Sweden	1.66	1.21	-2.53	-4.29	-1.04	-1.73
Switzerland	1.32	6.98	4.03	13.7	-0.425	-9.79
Thailand	20.9	8.09	29	22.9	0.0163	-16.5
Tunisia	-2.65	6.82	-7.9	1.35	-7.23	0.748
Turkey	-18.3	-5.01	-9.56	6.05	-0.528	-11.8
UAE	3.92	3.24	-13.6	-19.9	-0.869	0.86
UK	-10.2	2.92	2.25	14.6	-19.6	-7
Ukraine	-0.4	0.698	4	7.14	-0.846	0.88
USA	0.83	-0.0691	2.06	1.19	-0.776	0.691
Average	**1.32**	**-0.543**	**2.5**	**2.85**	**-2.07**	**-3.23**
Global Percentage Changes						
	Cases Early	**Deaths Early**	**IFR Early**	**Cases Proj.**	**Deaths Proj.**	**IFR Proj.**
Global	-0.717	-0.38	0.339	-0.278	0.978	1.26

Table S6- Impact of increasing assumed cross-country parameter variances by a factor of four. All reported outcomes measure percentage change in the given metric from baseline analysis.

Sensitivities to 0.25x change in variances						
Country	**Case Undercount Ratio**	**Death Undercount Ratio**	**Final Infection Rate**	**Final Death Rate**	**MAEN Infection**	**MAEN Death**
Albania	-3.13	1.75	23.6	14.1	2.02	1.68
Argentina	3.55	-0.491	-9.5	-11.1	7.99	-1.72

Armenia	-0.95	-5.74	-3.55	-5.72	2.05	5.99
Australia	-20	5.16	-12.3	34	2.45	3.26
Austria	-4.75	1.06	1.57	7.07	-1.11	5.23
Azerbaijan	7.04	-8.4	-24.9	-33.5	0.946	4.47
Bahrain	-5.26	9.8	7.24	28.7	3.58	5.34
Bangladesh	0.31	0.177	-4.52	-3.02	2	1.66
Belarus	-5.36	3.02	16.6	29.3	16.5	4.64
Belgium	12.8	-8.47	1.1	-20.4	27.6	6.36
Bolivia	3.82	2.61	32.9	13.2	0.607	2.54
Bosnia	7.14	-4.47	1.68	-9.96	3.57	0.14
Bulgaria	8.34	-9.12	27.1	16.1	1.83	2.38
Canada	8.92	-0.389	3.94	-9.84	20.7	2.9
Chile	-4.96	-1.98	10.1	16.4	-2.78	2.87
Colombia	-1.82	-1.47	11.3	9.63	-0.355	0.536
CostaRica	-15.9	32.4	-47.3	-48.9	3.59	18.4
Croatia	7.3	2.6	-7.94	291	2.95	4.82
Cuba	2.85	4.1	1	5.15	1.09	2.71
Cyprus	0.143	-3.75	0.038	-3.75	-0.155	-1.25
CzechRepublic	-4.15	-0.598	0.00585	4.68	0.417	2.96
Denmark	-2.62	-3.87	3.66	9.09	10.4	5.45
Ecuador	-10.8	-5.32	-5.77	6.02	-0.159	7.37
ElSalvador	-2.27	-7.69	94.8	63.7	2.1	1.26
Estonia	-9.78	-1.37	-18.1	-13.8	2.93	1.24
Ethiopia	-19.7	-13.4	-23.9	-31.2	0.644	0.609
Finland	-3.97	7.72	120	187	19.8	19.2
France	10.3	-6.64	1.06	-17.5	12.9	9.89
Germany	-4.7	1.71	4.61	10.8	1.37	7.52
Ghana	2.56	-4.17	21.4	18	1.62	-0.841
Greece	15.5	5.29	-2	-14.6	2.86	0.802
Hungary	1.58	-10.2	6.48	-5.42	25.3	8.33
Iceland	-1.33	34.8	232	153	3.44	20.2
India	8.55	-0.492	76.7	51.9	-16.1	-10.2
Indonesia	-11.9	-10.6	-13.4	-9.71	1.94	4.72
Iran	-5.18	-4.97	-0.287	-5.4	-0.192	8.17
Ireland	1.96	-2.23	21.8	11.9	6.51	-0.789
Israel	-10.4	3.35	7.15	24.1	1.26	1.28
Italy	4.41	-1.47	0.15	-8.53	21.2	-2.3
Japan	-40.2	-12	44.8	132	-15.7	38.1
Kazakhstan	-6.88	2.52	41.8	39.3	-0.0881	1.02
Kenya	-3.74	-10.4	1.39	-2.68	1.71	-2.93
Kuwait	0.669	-1.51	-6.39	-7.63	2.33	2.45
Kyrgyzstan	-2.96	-5.79	96.8	63.4	0.24	3.78
Latvia	-3.37	-0.247	19.3	25.3	-0.156	-0.616
Lithuania	1	-7.01	1.42	-7.81	0.577	-1.42
Luxembourg	-5.51	3.88	-21.5	30.2	1.17	2.66
Malaysia	-27.9	-6.68	18.6	97.9	-10.1	8.63
Maldives	-1.06	5.54	3.44	9.51	0.202	2.7
Mexico	23.3	20.5	-3.61	-9.12	4.23	2.31
Morocco	-40.4	-46.7	-25.5	-3.65	15.8	11.9
Nepal	-10.4	36.2	2.7	78.2	18.6	23
Netherlands	-3.81	-2.03	-6.58	-5.08	14	-2.05
NewZealand	-3.98	8.88	417	22.3	7.06	2.88
Nigeria	28	23.3	41.5	28.4	1.63	-0.272
NorthMacedonia	-1.94	0.000601	2.48	3.8	1.19	0.226
Norway	-8.8	0.636	-4.18	14.3	-4.5	5

Pakistan	-18.3	-11	10.2	13.4	0.0318	0.777
Panama	-1.55	0.656	1.09	2.72	3.4	1.4
Paraguay	6.74	25.2	-88	-90.1	1.66	9.98
Peru	-6.26	2.97	-10.7	28.6	0.672	112
Philippines	-9.64	-8.59	-19.4	-14.8	6.86	2.73
Poland	1.74	-2.7	21.7	18.6	9.54	3.22
Portugal	-12.6	1.9	-10.1	10.3	3.69	31.1
Qatar	-6.72	9.77	6.72	37.7	8.11	12.3
Romania	11.5	-2.31	4	-11.4	6.68	6.54
Russia	-0.0151	0.345	8.6	8.8	-1.7	0.153
Rwanda	-1.28	5.14	-27	-25.3	0.648	2.38
SaudiArabia	4.96	-2.97	-3.78	-6.67	7.81	2.28
Senegal	-2.89	0.971	-37.9	-37.3	0.388	1.44
Serbia	-4.4	-0.399	-9.21	-2.09	4.68	6.24
Singapore	-3.44	3.71	4.39	14.1	14.7	2.81
Slovakia	-5.06	12.2	-3.21	23.3	0.172	5.32
Slovenia	-5.44	-9.95	52.5	-7.61	8.5	0.452
SouthAfrica	14	4.92	-55.1	-53.7	11.8	21.3
SouthKorea	-1.81	-2.83	-23.2	-28.4	3.57	10.1
Spain	0.0473	-3.33	-1.24	-11.8	4.82	-0.976
Sweden	0.00817	-4.51	1.11	-1.79	1.95	8.03
Switzerland	1.15	-2.97	7.6	2.58	-0.745	2.71
Thailand	-22.4	-5.67	-11.7	18	0.313	41.9
Tunisia	1.59	-5.31	16.2	11	1.38	0.505
Turkey	0.149	-1.28	-0.0487	-0.0873	0.317	9.69
UAE	-5.04	-8.55	24.3	17.9	2.49	-1.33
UK	2.38	-1.86	0.265	0.0339	4.54	6.6
Ukraine	3.19	-2.61	19.6	10.8	3.94	-1.77
USA	0.313	-0.0401	-0.705	0.133	2.58	0.711
Average	**-2.43**	**-0.0221**	**12.3**	**13.8**	**4**	**6.43**
Global Percentage Changes and Elasticities						
	Cases Early	**Deaths Early**	**IFR Early**	**Cases Proj.**	**Deaths Proj.**	**IFR Proj.**
Global	0.784	0.0619	-0.717	-3.76	-4.16	-0.416

Sensitivity to Parametric Assumptions

Setup- We conducted sensitivity analysis changing all the major pre-specified (i.e. not estimated) model parameters to assess 1) How sensitive key results are to those parametric assumptions. 2) How overall model fit to data changes with changing those general parameters. In this analysis we changed each parameter by +/- 5%, and calculated the elasticities of the 12 outcome measures discussed in the previous section with respect to each parameter. Those elasticities are calculated as fractional change in the outcome measure divided by fractional change in the input parameter. As such, they are dimensionless, with values below one indicating minor to modest sensitivities.

Table S7 reports the parameters over which we conducted the sensitivity analysis, their base values, and an overview of the results where averages over country-level outcomes and fit measures are reported (first row) along with aggregate outcomes (second row; for a total of 12 outcomes per parameter in two rows). We report full country-level sensitivity results for the reported outcomes online, in the GitHub repository for the research. All reported numbers are elasticity values.

Results- Overall elasticities remain modest, under 1 in all cases and under 0.1 in half of the reported aggregates outcomes. Note that the mechanisms generating these elasticities are complex, as they emerge from new calibration of the model and thus incorporate various compensatory mechanisms and feedback effects. With that caveat in mind, we provide an overview of the results here and tables provide more in-depth outcomes.

The average residence time in hospitals has a small impact on death rates and IFR, as increasing the residence time reduces available beds and exacerbates hospital shortages. Increasing incubation period may modestly increase death under-count ratio and projected death rates, but slightly reduce projected infection rates. Impact of Onset-to-detection delay is somewhat similar. Post-detection resolution time has very limited impact on the outcomes, partly because once detection event has happened, the model behavior is not well constrained by data (except for the timing of death events outside hospitals). Relative risk of transmission by presymptomatics would increase undercounts, infections and deaths, with a stronger impact on case under-count (thus reducing IFR). Increasing this parameter would also slightly increase the gap between the model and death data (MAEN). Finally, increasing the sensitivity of COVID test would reduce undercounts in cases and deaths (but more for deaths, thus reducing IFR).

Table S7- Overview of parametric sensitivity results, reported as elasticities. Each parameter is followed by its base value, and two rows of outcomes identified on the top. First row includes averages of 4 outcomes and 2 fit measures across 86 countries. Second row includes measures calculated over all simulated populations on July 10th 2020 and March 20th 2021.

Parameter	**Ave Case Undercount Ratio**	**Ave Death Undercount Ratio**	**Ave 3/20/21 Infection Rate**	**Ave 3/20/21 Death Rate**	**Ave MAEN Infection Rate**	**Ave MAEN Death Rate**
	July 10 Cml. Cases	**July 10 Cml. Deaths**	**Historical IFR**	**3/20/21 Cml. Cases**	**3/20/21 Cml. Deaths**	**3/20/21 Cml. IFR**
Hospitalized Resolution Time (20 days)	-0.0273	-0.00809	0.179	0.22	-0.0248	0.0221
	-0.157	-0.0103	0.147	-0.0519	0.166	0.218
Incubation Period (5 days)	-0.0111	0.169	-0.255	0.305	-0.00266	0.0581
	0.037	-0.0651	-0.102	0.279	0.216	-0.0628
Onset to Detection Delay (5 days)	-0.0341	-0.0198	-0.28	0.098	0.00248	0.0105
	0.00657	0.00778	0.00124	0.251	0.332	0.0815
Post-Detection Phase Resolution Time (10 days)	-0.0209	-0.00222	0.0122	0.0264	-0.00154	0.00111
	-0.0176	-0.0011	0.0165	0.000542	0.0295	0.0289
Relative Risk of Transmission by Presymptomatic (1)	0.487	0.293	0.308	0.189	0.02	0.241
	0.507	0.306	-0.201	0.335	0.061	-0.274
Sensitivity of COVID Test (0.7)	-0.357	-0.577	-0.431	-0.481	0.0162	-0.124
	-0.212	-0.327	-0.115	-0.0564	-0.106	-0.0497

Country level outcome elasticities for model parameters

See the online Github repository at https://github.com/tseyanglim/CovidGlobal for country-level outcome tables.

Sensitivity of results to exclusion of major countries

We repeated the analysis in three additional setups, excluding the top five countries by population (India, USA, Indonesia, Pakistan, Nigeria), by true infections to date (USA, Mexico, Iran, Peru, Indonesia), and by reported infections to date (USA, Russia, India, UK, Spain) from the estimation and analysis. These analyses inform the sensitivity of overall findings to data from specific countries.

In each case we report the percentage of change in the country level and aggregate outcome measures (those defined and discussed above). Table S*8* summarizes the results; full country-level outcome tables are available on the online Github repository at https://github.com/tseyanglim/CovidGlobal.

Results- Overall, the impact of excluding the top countries from analysis on historical fit and outcome measures is modest: fit quality does not change by more than 1% in any of the settings. Moreover, the historical under-reporting ratios remains largely unchanged (changing by no more than 0.72%). Cases and deaths summed up over the sample naturally change when excluding the larger countries or those with more infections (the bottom rows for each analysis). More interesting is the impact on the longer-term projections: removing the major countries moves the estimated response parameters for the remaining countries towards somewhat weaker responses. As a result several countries, which in the base-case do not undergo uncontrolled outbreaks and very large projected infection rates, will do so in these sensitivity analyses. Thus, the projected average country-level infection and death rates, for the remaining sample (outcomes 3 and 4 in odd rows), grow significantly. These results further

underline the general sensitivity of long-term projections, and the fact that minor changes in estimated response function may have major implications for the long-term projections. The set of countries most at risk of this phase shift includes: Albania, Bahrain, Bangladesh, Bulgaria, Chile, Costa Rica, Ethiopia, Ghana, Kenya, North Macedonia, Pakistan, Panama, Paraguay, Peru, Qatar, Saudi Arabia, Senegal, and Ukraine.

Table S8-Sensitivity of outcomes (in percentage change from baseline) to exclusion of top five countries by true infection, population, and reported infection. Each analysis is specified by the removed countries and followed by two rows of outcomes identified on the top. First row includes averages of 4 outcomes and 2 fit measures across 86 countries. Second row includes measures calculated over all simulated populations on July 10th 2020 and March 20th 2021.

Removed Countries	**Ave Case Undercount Ratio**	**Ave Death Undercount Ratio**	**Ave 3/20/21 Infection Rate**	**Ave 3/20/21 Death Rate**	**Ave MAEN Infection Rate**	**Ave MAEN Death Rate**
	July 10 Cml. Cases	**July 10 Cml. Deaths**	**Historical IFR**	**3/20/21 Cml. Cases**	**3/20/21 Cml. Deaths**	**3/20/21 Cml. IFR**
Top True Infections: USA, Mexico, Iran, Peru, Indonesia	-0.715	-0.0218	5.81	0.532	-0.273	0.248
	-52	-48	8.37	-8.69	-9	-0.338
Top Populations: India, USA, Indonesia, Pakistan, Nigeria	-0.161	-0.0123	0.0902	0.398	-0.188	0.252
	-36.5	-33.4	4.94	-73.4	-73.1	1.07
Top Reported Infections: USA, Russia, India, UK, Spain	0.296	-0.206	-0.073	-0.957	0.399	-0.766
	-31.9	-43.4	-16.8	-65.2	-69.3	-11.8

S8 COMPLETE MODEL DOCUMENTATION

Below we provide complete model equations and units. The model in the .mdl format (which can be opened using Vensim software, and free Vensim model reader) is available with this appendix as well, and online at https://github.com/tseyanglim/CovidGlobal. Most equations are self-explanatory. The "[…]" notation is used to subscript variables over a set of members. For example, the subscript "Rgn" is used to identify different countries. Therefore [Rgn] indicates that a variable is defined separately for each member of the set "Rgn". Other subscript ranges used in the equations are:

expnt: Used for numerically solving the probability of missing symptoms equation.

pdim: Used for setting policy levels for a few variables.

Priors: Used for implementing the random effects estimation components. Each estimated parameter is mapped into an element of this subscript to simplify vector-based calculations.

Series: The data series (Infection, Death, Recovery).

TstSts: The test status including those confirmed ('Tested') and those unconfirmed ('Notest').

Complete equations and units

1) a[Rgn] = XIDZ (Potential Test Demand from Susceptible Population[Rgn] , Positive Candidates Interested in Testing Poisson Subset Adj[Rgn] , 1) Units: dmnl
2) AbsPrcErr[Rgn,Series] = if then else (DataIncluded[Rgn] = 0, :NA:, ZIDZ (abs (FlowResiduals[Rgn,Series]) , DataFlowOverTime[Rgn,Series])) Units: dmnl
3) AbsStd[Priors] = 0.2, 0.3, 0.2, 0.2, 0.0005, 0.2, 30, 0.03, 6, 0.1, 0.1, 0.1, 0.8, 0.1, 1e-05, 10, 0.01, 0.005, 0.03, 10, 10, 10, 0.02
4) Active Test Rate[Rgn] = if then else (Time < New Testing Time , DataTestRate[Rgn] , External Test Rate[Rgn]) Units: Person/Day
5) ActiveAve[PriorEndoAve] = INITIAL(InputAve[PriorEndoAve] * (1 - SW EndoAve) + SW EndoAve * CalcAve[PriorEndoAve])
6) ActiveAve[PMT] = InputAve[PMT]
7) Activities Allowed by Government[Rgn] = 1 Units: dmnl
8) Additional Asymptomatic Post Detection[Rgn] = Weighted Infected Post Detection Gate[Rgn] * Additional Asymptomatic Relative to Symptomatic[Rgn] / (1 + Additional Asymptomatic Relative to Symptomatic[Rgn]) Units: Person
9) Additional Asymptomatic Relative to Symptomatic[Rgn] = ZIDZ (Total Asymptomatic Fraction Net[Rgn] - exp (- Covid Acuity[Rgn]) , 1 - Total Asymptomatic Fraction Net[Rgn]) Units: dmnl
10) AdvCntrs[Rgn] = 1 Units: dmnl
11) All Recovery[Rgn] = Recovery of Confirmed[Rgn] + Recovery of Untested[Rgn] + sum (Hospital Discharges[Rgn,TstSts!]) Units: Person/Day
12) Allocated Fraction COVID Hospitalized[Rgn] = min (1, (- Expected Positive Poisson Covid Patients[Rgn] + Sqrt (Expected Positive Poisson Covid Patients[Rgn] ^ 2 + 4 * Effective Hospital Capacity[Rgn] * Effective Hospital Capacity[Rgn])) / (2 * Effective Hospital Capacity[Rgn])) Units: dmnl

13) Allocated Fration NonCOVID Hospitalized[Rgn] = SMOOTHI (Allocated Fraction COVID Hospitalized[Rgn] ^ 2, Hospital Adj T , 1) Units: dmnl
14) alp[Rgn,Infection] = min (maxAlp , ialp * alpR[Rgn])
15) alp[Rgn,Death] = min (1, dalp * alpR[Rgn])
16) alp[Rgn,Test] = min (1, talp * alpR[Rgn]) Units: dmnl
17) alpR[Rgn] = 1 Units: dmnl
18) Area of Region[Rgn] = GET VDF CONSTANTS(Constant Data File , 'DataConstants[Rgn]', 5) Units: Km*Km
19) Average Acuity Hospitalized[Rgn,Tested] = Average Acuity of Positively Tested[Rgn] * XIDZ ((1 - Probability of Missing Acuity Signal at Hospitals[Rgn,Tested] * Fraction Poisson not Hospitalized[Rgn,Tested] ^ 2) , 1 - Fraction Poisson not Hospitalized[Rgn,Tested] , 2 * Probability of Missing Acuity Signal at Hospitals[Rgn,Tested])
20) Average Acuity Hospitalized[Rgn,Notest] = ZIDZ (Average Acuity of Untested Poisson Subset[Rgn] * (1 - Probability of Missing Acuity Signal at Hospitals[Rgn,Notest] * Fraction Poisson not Hospitalized[Rgn,Notest] ^ 2) , 1 - Fraction Poisson not Hospitalized[Rgn,Notest]) Units: dmnl
21) Average Acuity Not Hospitalized[Rgn,Notest] = ZIDZ (Average Acuity Not Hospitalized Poisson[Rgn,Notest] * Infectious not Tested or in Hospitals Poisson[Rgn] , "Infected Unconfirmed Post-Detection"[Rgn])
22) Average Acuity Not Hospitalized[Rgn,Tested] = Average Acuity Not Hospitalized Poisson[Rgn,Tested] Units: dmnl
23) Average Acuity Not Hospitalized Poisson[Rgn,Tested] = Max (0, Probability of Missing Acuity Signal at Hospitals[Rgn,Tested] * Average Acuity of Positively Tested[Rgn] * Fraction Poisson not Hospitalized[Rgn,Tested])
24) Average Acuity Not Hospitalized Poisson[Rgn,Notest] = Max (0, Probability of Missing Acuity Signal at Hospitals[Rgn,Notest] * Average Acuity of Untested Poisson Subset[Rgn] * Fraction Poisson not Hospitalized[Rgn,Notest]) Units: dmnl
25) Average Acuity of Positively Tested[Rgn] = Covid Acuity[Rgn] * XIDZ ((1 - Prob Missing Symptom[Rgn] * Fraction Interested not Tested[Rgn] ^ 2) , 1 - Fraction Interested not Tested[Rgn] , 2 * Prob Missing Symptom[Rgn]) Units: dmnl
26) Average Acuity of Untested Poisson Subset[Rgn] = ZIDZ (Poisson Subset Reaching Test Gate[Rgn] * Covid Acuity[Rgn] - Positive Tests of Infected[Rgn] * Average Acuity of Positively Tested[Rgn] , Poisson Subset Not Tested Passing Gate[Rgn]) Units: dmnl
27) b[Rgn] = ZIDZ (Testing on Living[Rgn] - Positive Candidates Interested in Testing Poisson Subset Adj[Rgn] - Potential Test Demand from Susceptible Population[Rgn] , Positive Candidates Interested in Testing Poisson Subset Adj[Rgn]) Units: dmnl
28) Base Fatality Rate for Unit Acuity[Rgn] = 0.0006 Units: dmnl
29) Base Fatality Rate for Unit Acuity Net[Rgn] = INITIAL(Base Fatality Rate for Unit Acuity[Rgn] * (1 - SW Gen[BsFtRt]) + SW Gen[BsFtRt] * InputAve[BsFtRt]) Units: dmnl
30) BaseError = 5 Units: Person
31) Baseline Daily Fraction Susceptible Seeking Tests[Rgn] = 0.001 Units: 1/Day
32) Baseline Fatality Multiplier[Rgn] = INITIAL(Demographic Impact on Fatality Relative to China[Rgn] * Base Fatality Rate for Unit Acuity Net[Rgn] * Liver Disease Impact on Fatality[Rgn] * Obesity Impact on Fatality[Rgn] * Chronic Impact on Fatality[Rgn]) Units: dmnl

33) Baseline Risk of Transmission by Asymptomatic[Rgn] = INITIAL(Baseline Transmission Multiplier for Untested Symptomatic * Multiplier Transmission Risk for Asymptomatic Net[Rgn]) Units: dmnl
34) Baseline Transmission Multiplier for Untested Symptomatic = 1 Units: dmnl
35) Bed per Square Kilometer[Rgn] = INITIAL(Nominal Hospital Capacity[Rgn] / Area of Region[Rgn]) Units: Person/(Km*Km)
36) Beds per Thousand Population[Rgn] = GET VDF CONSTANTS(Constant Data File , 'DataConstants[Rgn]', 11) Units: dmnl
37) CalcAve[Priors] = INITIAL(sum (RegionalInputs[Priors,Rgn!]) / ELMCOUNT(Rgn))
38) cft[Rgn,p2] = lnymix[Rgn,p2]
39) cft[Rgn,p3] = lnymix[Rgn,p3] - lnymix[Rgn,p2]
40) cft[Rgn,p4] = (ln (min (100, Max (1e-06, ZIDZ (lnymix[Rgn,p4] - lnymix[Rgn,p2] , lnymix[Rgn,p3] - lnymix[Rgn,p2]) / ln (2))))) Units: dmnl
41) Chng Cml Dth Untst Untrt[Rgn] = Deaths of Symptomatic Untested[Rgn] - Post Mortem Test Rate[Rgn] * Frac Post Mortem from Untreated[Rgn] Units: Person/Day
42) Chronic Death Rate[Rgn] = GET VDF CONSTANTS(Constant Data File , 'DataConstants[Rgn]', 17) Units: dmnl
43) Chronic Impact on Fatality[Rgn] = INITIAL((Chronic Death Rate[Rgn] / MeanChronic) ^ Sens Chronic Impact Net[Rgn]) Units: dmnl
44) Cml Death Frac In Hosp[Rgn] = XIDZ (Cumulative Deaths at Hospital[Rgn,Tested] + Cumulative Deaths at Hospital[Rgn,Notest] , Cumulative Deaths[Rgn] , 1) Units: dmnl
45) Cml Death fraction in hospitals large enough = sum (if then else (Cml Death Frac In Hosp[Rgn!] < MinHspDTresh , 1, 0)) Units: dmnl
46) Cml Death Hsp Inc[Rgn,Tested] = Hospitalized Infectious Deaths[Rgn,Tested] + PostMortemCorrection[Rgn]
47) Cml Death Hsp Inc[Rgn,Notest] = Hospitalized Infectious Deaths[Rgn,Notest] - PostMortemCorrection[Rgn] Units: Person/Day
48) Cml Known Death Frac Hosp[Rgn] = XIDZ (Cumulative Deaths at Hospital[Rgn,Tested] , Cumulative Deaths[Rgn] , 1) Units: dmnl
49) CmltErrPW = 2 Units: dmnl
50) CmltPenaltyScl = 0 Units: dmnl
51) CmltToInclude[Series] = 0, 0, 0 Units: dmnl
52) Confirmation Impact on Contact[Rgn] = 0.002 Units: dmnl
53) Confirmed Recovered[Rgn] = INTEG(Recovery of Confirmed[Rgn] , 0) Units: Person
54) Constant Data File :IS: 'CovidModelInputs - ConstantData.vdf'
55) Contacts Relative to Normal[Rgn] = min (Voluntary Reduction in Contacts[Rgn] , Activities Allowed by Government[Rgn]) Units: dmnl
56) Continue without Testing[Rgn] = Reaching Testing Gate[Rgn] - Symptomatic Infected to Testing[Rgn] - Untested symptomatic Infected to Hospital[Rgn] Units: Person/Day
57) Count Missed Death[Rgn] = if then else (Excess Death Start Count[Rgn] = :NA:, 0, if then else (Time >= Excess Death Start Count[Rgn] :AND: Time <= Excess Death End Count[Rgn] , Cml

Death Hsp Inc[Rgn,Notest] + Chng Cml Dth Untst Untrt[Rgn] , 0)) Units: Person/Day

58) Covid Acuity[Rgn] = Flu Acuity * Covid Acuity Relative to Flu Net[Rgn] Units: dmnl
59) Covid Acuity Relative to Flu[Rgn] = 6 Units: dmnl
60) Covid Acuity Relative to Flu Net[Rgn] = INITIAL(Covid Acuity Relative to Flu[Rgn] * (1 - SW Gen[Acty]) + SW Gen[Acty] * InputAve[Acty]) Units: dmnl
61) Covid Poisson Fraction in Hospital[Rgn] = ZIDZ (Total Covid Hospitalized[Rgn] , Infectious not Tested or in Hospitals Poisson[Rgn] + Infectious Confirmed Not Hospitalized[Rgn] + Total Covid Hospitalized[Rgn]) Units: dmnl
62) CRW[Rgn] Units: dmnl
63) Cumulative Cases[Rgn] = INTEG(New Cases[Rgn] , 0) Units: Person
64) Cumulative Confirmed Cases[Rgn] = Infectious Confirmed Not Hospitalized[Rgn] + Hospitalized Infectious[Rgn,Tested] + Cumulative Deaths of Confirmed[Rgn] + Cumulative Confirmed Recovered[Rgn] Units: Person
65) Cumulative Confirmed Recovered[Rgn] = Confirmed Recovered[Rgn] + Cumulative Recovered at Hospitals[Rgn,Tested] Units: Person
66) Cumulative Death Fraction[Rgn] = ZIDZ (Cumulative Deaths[Rgn] , Cumulative Deaths[Rgn] + Cumulative Recoveries[Rgn]) Units: dmnl
67) Cumulative Deaths[Rgn] = INTEG(Death Rate[Rgn] , 0) Units: Person
68) Cumulative Deaths at Hospital[Rgn,TstSts] = INTEG(Cml Death Hsp Inc[Rgn,TstSts] , 0) Units: Person
69) Cumulative Deaths of Confirmed[Rgn] = Cumulative Deaths at Hospital[Rgn,Tested] + Cumulative Deaths of Confirmed Untreated[Rgn] Units: Person
70) Cumulative Deaths of Confirmed Untreated[Rgn] = INTEG(Deaths of Confirmed[Rgn] + Post Mortem Test Untreated[Rgn] , 0) Units: Person
71) Cumulative Deaths Untested Untreated[Rgn] = INTEG(Chng Cml Dth Untst Untrt[Rgn] , 0) Units: Person
72) Cumulative Fraction Total Cases Hospitalized[Rgn] = ZIDZ (sum (Cumulative Deaths at Hospital[Rgn,TstSts!] + Cumulative Recovered at Hospitals[Rgn,TstSts!] + Hospitalized Infectious[Rgn,TstSts!]) , Cumulative Cases[Rgn]) Units: dmnl
73) Cumulative Missed Death[Rgn] = INTEG(Count Missed Death[Rgn] , 0) Units: Person
74) Cumulative Negative Tests[Rgn] = INTEG(Negative Test Results[Rgn] , 0) Units: Person
75) Cumulative Recovered at Hospitals[Rgn,TstSts] = INTEG(Hospital Discharges[Rgn,TstSts] , 0) Units: Person
76) Cumulative Recoveries[Rgn] = INTEG(All Recovery[Rgn] , 0) Units: Person
77) Cumulative Tests Conducted[Rgn] = INTEG(SimTestRate[Rgn] , 0) Units: Person
78) Cumulative Tests Data[Rgn] = INTEG(TstInc[Rgn] , 0) Units: Person
79) Current Test Rate per Capita[Rgn] = INITIAL(if then else (DataLastTestRate[Rgn] = :NA:, 0, DataLastTestRate[Rgn] / Population[Rgn])) Units: 1/Day
80) dalp = 0.1 Units: dmnl

81) Data Excess Deaths[Rgn] = GET VDF CONSTANTS(Constant Data File , 'DataConstants[Rgn]', 15) Units: Person
82) Data Pseudo Case Fatality[Rgn] = ZIDZ (DataCmltDeath[Rgn] , DataCmltInfection[Rgn]) Units: dmnl
83) DataAttentionTime[Rgn] = GET VDF CONSTANTS(Constant Data File , 'DataConstants[Rgn]', 9) Units: Day
84) DataCmltDeath[Rgn] Units: Person
85) DataCmltInfection[Rgn] Units: Person
86) DataCmltOverTime[Rgn,Infection] :RAW: := DataCmltInfection[Rgn]
87) DataCmltOverTime[Rgn,Death] :RAW: := DataCmltDeath[Rgn]
88) DataCmltOverTime[Rgn,Test] = DataCmltTest[Rgn] Units: Person
89) DataCmltTest[Rgn] Units: Person
90) DataFlowDeath[Rgn] :RAW: Units: Person/Day
91) DataFlowInfection[Rgn] Units: Person/Day
92) DataFlowOverTime[Rgn,Infection] :RAW: := DataFlowInfection[Rgn]
93) DataFlowOverTime[Rgn,Death] :RAW: := DataFlowDeath[Rgn]
94) DataFlowOverTime[Rgn,Test] :RAW: := DataTestRate[Rgn] Units: Person/Day
95) DataFlowRecovery[Rgn] :RAW: Units: Person/Day
96) DataIncluded[Rgn] = if then else (Max (Cumulative Deaths[Rgn] , Max (Cumulative Confirmed Cases[Rgn] , DataCmltInfection[Rgn])) > ThrsInc[Rgn] , 1, 0) * DataLimitFromTime Units: dmnl
97) DataLastTestRate[Rgn] = INITIAL(GET DATA AT TIME (DataTestRate[Rgn] , min (LastTestDate[Rgn] , New Testing Time))) Units: Person/Day
98) DataLimitFromTime = if then else (Time > Max Time Data Used , 0, 1) Units: dmnl
99) DataTestCapacity[Rgn] Units: Person/Day
100) DataTestRate[Rgn] Units: Person/Day
101) Day of First Case Report in JHU Database = 99 Units: Day
102) Days per Year = 365 Units: Day/Year
103) Death Rate[Rgn] = Deaths of Confirmed[Rgn] + Deaths of Symptomatic Untested[Rgn] + sum (Hospitalized Infectious Deaths[Rgn,TstSts!]) Units: Person/Day
104) Deaths of Confirmed[Rgn] = Tested Untreated Resolution[Rgn] * Fatality Rate Untreated[Rgn,Tested] Units: Person/Day
105) Deaths of Symptomatic Untested[Rgn] = Infectious not Tested or in Hospitals Poisson[Rgn] / "Post-Detection Phase Resolution Time" * Fatality Rate Untreated[Rgn,Notest] Units: Person/Day
106) Delay Order = 1 Units: dmnl
107) Demographic Impact on Fatality Relative to China[Rgn] = GET VDF CONSTANTS(Constant Data File , 'DataConstants[Rgn]', 12) Units: dmnl
108) Di[Rgn,Series] = DataFlowOverTime[Rgn,Series] Units: Person/Day
109) Discount Rate Annual = 0.03 Units: 1/Year
110) Discount Rate per Day = INITIAL(Discount Rate Annual / Days per Year) Units: 1/Day
111) Dread Factor in Risk Perception[Rgn] = 25 Units: dmnl

112) Dread Factor in Risk Perception Net[Rgn] = if then else (Response Policy Time On < Time , Dread Factor Policy * Response Policy Weight[dfcP] + (1 - Response Policy Weight[dfcP]) * Dread Factor in Risk Perception[Rgn] , Dread Factor in Risk Perception[Rgn]) Units: dmnl
113) Dread Factor Policy = 3000 Units: dmnl
114) Effective Hospital Capacity[Rgn] = Nominal Hospital Capacity[Rgn] * Normalized Hospital density[Rgn] ^ Impact of Population Density on Hospital Availability[Rgn] Units: Person
115) eps = 0.001 Units: Person/Day
116) Excess Death End Count[Rgn] = GET VDF CONSTANTS(Constant Data File , 'DataConstants[Rgn]', 14) Units: Day
117) Excess Death Mean Frac = 0.9 Units: dmnl
118) Excess Death Range Frac = 0.2 Units: dmnl
119) Excess Death Rate Error[Rgn] = if then else (Data Excess Deaths[Rgn] < 50, 0, ZIDZ (Cumulative Missed Death[Rgn] - Excess Death Mean Frac * Data Excess Deaths[Rgn] , Excess Death Range Frac * Data Excess Deaths[Rgn]) ^ 4) Units: dmnl
120) Excess Death Start Count[Rgn] = GET VDF CONSTANTS(Constant Data File , 'DataConstants[Rgn]', 13) Units: Day
121) Expected Positive Poisson Covid Patients[Rgn] = sum (Potential Hospital Demand[Rgn,TstSts!]) * "Post-Detection Phase Resolution Time" Units: Person
122) expnt : (p2-p4)
123) External Test Rate[Rgn] = Population[Rgn] * Policy Test Rate[Rgn] Units: Person/Day
124) Extrapolated Estimator[Rgn] = if then else (Covid Acuity Relative to Flu Net[Rgn] > 1, cft[Rgn,p2] + cft[Rgn,p3] * (Covid Acuity Relative to Flu Net[Rgn] - 1) ^ cft[Rgn,p4] , lnymix[Rgn,p2]) Units: dmnl
125) F[Rgn] = Utility from Normal Activities[Rgn] / (Utility from Limited Activities[Rgn] + Utility from Normal Activities[Rgn]) Units: dmnl
126) F0[Rgn] = INITIAL(F[Rgn]) Units: dmnl
127) Fatality Rate Treated[Rgn,TstSts] = min (1, Baseline Fatality Multiplier[Rgn] * Impact of Treatment on Fatality Rate[Rgn] * Average Acuity Hospitalized[Rgn,TstSts] ^ Sensitivity of Fatality Rate to Acuity Net[Rgn]) Units: dmnl
128) Fatality Rate Untreated[Rgn,TstSts] = min (1, Baseline Fatality Multiplier[Rgn] * Average Acuity Not Hospitalized Poisson[Rgn,TstSts] ^ Sensitivity of Fatality Rate to Acuity Net[Rgn]) Units: dmnl
129) Final Test Rate Per Capita[Rgn] = INITIAL(Current Test Rate per Capita[Rgn] + Weight Max in Test Goal * (Max Test Rate per Capita - Current Test Rate per Capita[Rgn])) Units: 1/Day
130) FINAL TIME = 250 Units: Day
131) FlowResiduals[Rgn,Series] = if then else (DataFlowOverTime[Rgn,Series] = :NA:, :NA:, DataFlowOverTime[Rgn,Series] - SimFlowOverTime[Rgn,Series]) Units: Person/Day
132) FlowToInclude[Series] = 1, 1, 0 Units: dmnl
133) Flu Acuity = 1 Units: dmnl

134) Flu Acuity Relative to Covid[Rgn] = Flu Acuity / Covid Acuity[Rgn] Units: dmnl
135) Frac Post Mortem from Untreated[Rgn] = SMOOTHI (ZIDZ (Deaths of Symptomatic Untested[Rgn] , Deaths of Symptomatic Untested[Rgn] + Hospitalized Infectious Deaths[Rgn,Notest]) , Post Mortem Test Delay , 1) Units: dmnl
136) FracThresh = 0.001 Units: dmnl
137) Fraction Covid Death In Hospitals Previously Tested[Rgn] = ZIDZ (Hospitalized Infectious Deaths[Rgn,Tested] , sum (Hospitalized Infectious Deaths[Rgn,TstSts!])) Units: dmnl
138) Fraction Covid Hospitalized Positively Tested[Rgn] = ZIDZ (Hospitalized Infectious[Rgn,Tested] , Total Covid Hospitalized[Rgn]) Units: dmnl
139) Fraction Interested not Tested[Rgn] = 1 - ZIDZ (Total Test on Covid Patients[Rgn] , Positive Candidates Interested in Testing Poisson Subset[Rgn]) Units: dmnl
140) Fraction Interseted not Correctly Tested[Rgn] = 1 - (1 - Fraction Interested not Tested[Rgn]) * Sensitivity of COVID Test Units: dmnl
141) Fraction of Additional Symptomatic[Rgn] = Additional Asymptomatic Relative to Symptomatic[Rgn] / (1 + Additional Asymptomatic Relative to Symptomatic[Rgn]) Units: dmnl
142) Fraction of Fatalities Screened Post Mortem[Rgn] = Indicated Fraction Post Mortem Testing[Rgn] * Switch for Government Response[Rgn] Units: dmnl
143) Fraction of Population Hospitalized for Covid[Rgn] = Total Covid Hospitalized[Rgn] / Population[Rgn] Units: dmnl
144) Fraction Poisson not Hospitalized[Rgn,Tested] = exp (- Average Acuity of Positively Tested[Rgn] * (1 - Probability of Missing Acuity Signal at Hospitals[Rgn,Tested]))
145) Fraction Poisson not Hospitalized[Rgn,Notest] = exp (- Average Acuity of Untested Poisson Subset[Rgn] * (1 - Probability of Missing Acuity Signal at Hospitals[Rgn,Notest])) Units: dmnl
146) Fraction Seeking Test[Rgn] = 1 Units: dmnl
147) Fraction Tests Positive[Rgn] = ZIDZ (Positive Tests of Infected[Rgn] , Testing on Living[Rgn]) Units: dmnl
148) Fraction Tests Positive Data[Rgn] = min (1, ZIDZ (DataFlowInfection[Rgn] , Active Test Rate[Rgn])) Units: dmnl
149) Fractional Value of Limited Activities = 0.5 Units: dmnl
150) Global Cases = sum (Cumulative Cases[Rgn!]) Units: Person
151) Global Deaths = sum (Cumulative Deaths[Rgn!]) Units: Person
152) Global IFR = ZIDZ (Global Deaths , Global Cases) Units: dmnl
153) Government Response Start Time[Rgn] = INITIAL(DataAttentionTime[Rgn] + Day of First Case Report in JHU Database) Units: Day
154) Hazard of Symptomatic Infection[Rgn] = Infection Rate[Rgn] / Susceptible[Rgn] * (1 - Total Asymptomatic Fraction Net[Rgn]) Units: 1/Day
155) Herd Immunity Fraction = 0.8 Units: dmnl
156) Hospital Adj T = 1 Units: Day
157) Hospital Admission Infectious[Rgn,TstSts] = Hospital Admits All[Rgn,TstSts] Units: Person/Day

158) Hospital Admit Ratio[Rgn,TstSts] = XIDZ (Hospital Admits All[Rgn,TstSts] , Potential Hospital Demand[Rgn,TstSts] , 1) Units: dmnl
159) Hospital Admits All[Rgn,Tested] = Hospital Demand from Tested[Rgn] * Allocated Fraction COVID Hospitalized[Rgn]
160) Hospital Admits All[Rgn,Notest] = Hospital Demand from Not Tested[Rgn] * Allocated Fraction COVID Hospitalized[Rgn] Units: Person/Day
161) Hospital Demand from Not Tested[Rgn] = Poisson Subset Not Tested Passing Gate[Rgn] * (1 - exp (- Average Acuity of Untested Poisson Subset[Rgn] * (1 - PMAS Unconfirmed for Hospital Demand[Rgn]))) Units: Person/Day
162) Hospital Demand from Tested[Rgn] = Positive Tests of Infected[Rgn] * (1 - exp (- Average Acuity of Positively Tested[Rgn] * (1 - PMAS Confirmed for Hospital Demand[Rgn]))) Units: Person/Day
163) Hospital Discharges[Rgn,TstSts] = (1 - Fatality Rate Treated[Rgn,TstSts]) * Hospital Outflow Covid Positive[Rgn,TstSts] Units: Person/Day
164) Hospital Outflow Covid Positive[Rgn,TstSts] = Hospitalized Infectious[Rgn,TstSts] / Hospitalized Resolution Time Units: Person/Day
165) Hospitalized CFR Cumulative[Rgn,TstSts] = ZIDZ (Cumulative Deaths at Hospital[Rgn,TstSts] , Cumulative Deaths at Hospital[Rgn,TstSts] + Cumulative Recovered at Hospitals[Rgn,TstSts]) Units: dmnl
166) Hospitalized Infectious[Rgn,TstSts] = INTEG(Hospital Admission Infectious[Rgn,TstSts] - Hospitalized Infectious Deaths[Rgn,TstSts] - Hospital Discharges[Rgn,TstSts] , 0) Units: Person
167) Hospitalized Infectious Deaths[Rgn,TstSts] = Fatality Rate Treated[Rgn,TstSts] * Hospital Outflow Covid Positive[Rgn,TstSts] Units: Person/Day
168) Hospitalized Resolution Time = 20 Units: Day
169) Hospitalized True CFR[Rgn] = ZIDZ (sum (Hospitalized Infectious Deaths[Rgn,TstSts!]) , sum (Hospital Outflow Covid Positive[Rgn,TstSts!])) Units: dmnl
170) Hospitalized True CFR Cumulative[Rgn] = ZIDZ (sum (Cumulative Deaths at Hospital[Rgn,TstSts!]) , sum (Cumulative Deaths at Hospital[Rgn,TstSts!] + Cumulative Recovered at Hospitals[Rgn,TstSts!])) Units: dmnl
171) ialp = 0.1 Units: dmnl
172) Impact of Population Density on Hospital Availability[Rgn] = 0.72 Units: dmnl
173) Impact of Treatment on Fatality Rate[Rgn] = 0.32 Units: dmnl
174) Incubation Period = 5.6 Units: Day
175) Indicated fraction negative demand tested[Rgn] = 1 - exp (Flu Acuity * (Prob Missing Symptom[Rgn] - 1)) Units: dmnl
176) Indicated fraction positive demand tested[Rgn] = 1 - exp (Covid Acuity[Rgn] * (Prob Missing Symptom[Rgn] - 1)) Units: dmnl
177) Indicated Fraction Post Mortem Testing[Rgn] = Fraction Covid Death In Hospitals Previously Tested[Rgn] ^ Sensitivity Post Mortem Testing to Capacity[Rgn] Units: dmnl
178) Indicated Risk of Life Loss[Rgn] = min (1, Switch for Government Response[Rgn] * Perceived Hazard of Infection[Rgn] * Dread Factor in Risk Perception Net[Rgn] * PseudoCFR / Discount Rate per Day) Units: dmnl

179) Infected pre Detection[Rgn] = INTEG(Onset of Symptoms[Rgn] - Continue without Testing[Rgn] - Symptomatic Infected to Testing[Rgn] - Untested symptomatic Infected to Hospital[Rgn] , 0) Units: Person
180) "Infected Unconfirmed Post-Detection"[Rgn] = INTEG(Continue without Testing[Rgn] - Deaths of Symptomatic Untested[Rgn] - Recovery of Untested[Rgn] , 0) Units: Person
181) Infection Rate[Rgn] = Infectious Contacts[Rgn] * (Susceptible[Rgn] / Population[Rgn]) * Weather Effect on Transmission[Rgn] Units: Person/Day
182) Infectious Confirmed Not Hospitalized[Rgn] = INTEG(Positive Testing of Infected Untreated[Rgn] - Deaths of Confirmed[Rgn] - Recovery of Confirmed[Rgn] , 0) Units: Person
183) Infectious Contacts[Rgn] = ("Pre-Symptomatic Infected"[Rgn] * Transmission Multiplier Presymptomatic[Rgn] + Infected pre Detection[Rgn] * Transmission Multiplier Pre Detection[Rgn] + (Additional Asymptomatic Post Detection[Rgn] + "Poisson Not-tested Asymptomatic"[Rgn]) * Baseline Risk of Transmission by Asymptomatic[Rgn] + (Infectious not Tested or in Hospitals Poisson[Rgn] - "Poisson Not-tested Asymptomatic"[Rgn]) * Baseline Transmission Multiplier for Untested Symptomatic + Infectious Confirmed Not Hospitalized[
184) Rgn] * Transmission Multiplier for Confirmed[Rgn] + sum (Hospitalized Infectious[Rgn,TstSts!] * Transmission Multiplier for Hospitalized[Rgn,TstSts!])) * Reference Force of Infection[Rgn] * Contacts Relative to Normal[Rgn] Units: Person/Day
185) Infectious not Tested or in Hospitals Poisson[Rgn] = "Infected Unconfirmed Post-Detection"[Rgn] - Additional Asymptomatic Post Detection[Rgn] Units: Person
186) Initial Population[Rgn] = GET VDF CONSTANTS(Constant Data File , 'DataConstants[Rgn]', 1) Units: Person
187) INITIAL TIME = 30 Units: Day
188) InpAveErr = INITIAL(sum (InpAveErrCmp[PriorEndoAve!]))
189) InpAveErrCmp[PriorEndoAve] = INITIAL((abs (CalcAve[PriorEndoAve] - InputAve[PriorEndoAve]) / Max (1e-06, CalcAve[PriorEndoAve]) * SW EndoAve))
190) InputAve[Priors] = 1, 1.8, 0.47, 1, 0.0009, 0.81, 58, 0.017, 6.2, 0.1, 0.24, 0.4, 2.27, 0.52, 0.00055, 0.76, 5.9, 2.07, 0.55, 1e-06, 1e-06, 1e-06, 0.28
191) IrD : Travel,InformalDeath
192) Known death fraction in hospitals large enough = sum (if then else (Cml Known Death Frac Hosp[Rgn!] < MinHspDTreshAdv , 1, 0) * AdvCntrs[Rgn!]) Units: dmnl
193) LastTestDate[Rgn] = INITIAL(GET DATA Last TIME (DataTestRate[Rgn])) Units: Day
194) Liver Disease Impact on Fatality[Rgn] = INITIAL((Liver Disease Rate[Rgn] / MeanLiver) ^ Sens Liver Impact Net[Rgn]) Units: dmnl
195) Liver Disease Rate[Rgn] = GET VDF CONSTANTS(Constant Data File , 'DataConstants[Rgn]', 18) Units: dmnl
196) lnymix[Rgn,expnt] = - ln (Max (1e-06, 1 - Ymix[Rgn,expnt])) Units: dmnl
197) lnymix 0[Rgn,expnt] = - ln (Max (1e-06, 1 - Ymix[Rgn,expnt])) Units: dmnl
198) Max Test Rate per Capita = 0.001 Units: 1/Day
199) Max Time Data Used = 247 Units: Day
200) maxAlp = 1 Units: dmnl

201) MaxData[Rgn] = INITIAL(GET DATA MAX (DataCmltInfection[Rgn] , 0, 500))
Units: Person
202) MaxRTresh = 8 Units: dmnl
203) MeanChronic = GET VDF CONSTANTS(Constant Data File , 'MeanChronic', 1)
Units: dmnl
204) MeanLiver = GET VDF CONSTANTS(Constant Data File , 'MeanLiver', 1) Units: dmnl
205) MeanObesity = GET VDF CONSTANTS(Constant Data File , 'MeanObesity', 1)
Units: dmnl
206) Min Contact Fraction[Rgn] = 0.04 Units: dmnl
207) Min Excess Death Attributable to COVID = 0.5 Units: dmnl
208) MinAdjT = 1 Units: Day
209) MinHspDTresh = 0.2 Units: dmnl
210) MinHspDTreshAdv = 0.8 Units: dmnl
211) MinSuscTresh = 0.7 Units: dmnl
212) Mu[Rgn,Series] = Max (eps , SimFlowOverTime[Rgn,Series]) Units: Person/Day
213) Multiplier Recent Infections to Test[Rgn] = 45 Units: dmnl
214) Multiplier Transmission Risk for Asymptomatic[Rgn] = 0.3 Units: dmnl
215) Multiplier Transmission Risk for Asymptomatic Net[Rgn] = INITIAL(Multiplier Transmission Risk for Asymptomatic[Rgn] * (1 - SW Gen[MTrAsym]) + SW Gen[MTrAsym] * InputAve[MTrAsym]) Units: dmnl
216) NBL1[Rgn,Series] = if then else (DataFlowOverTime[Rgn,Series] = 0, - ln (1 + alp[Rgn,Series] * Mu[Rgn,Series]) / alp[Rgn,Series] , 0) Units: dmnl
217) NBL2[Rgn,Series] = if then else (DataFlowOverTime[Rgn,Series] > 0, GAMMA LN (Di[Rgn,Series] + 1 / alp[Rgn,Series]) - GAMMA LN (1 / alp[Rgn,Series]) - GAMMA LN (Di[Rgn,Series] + 1) - (Di[Rgn,Series] + 1 / alp[Rgn,Series]) * ln (1 + alp[Rgn,Series] * Mu[Rgn,Series]) + Di[Rgn,Series] * (ln (alp[Rgn,Series]) + ln (Mu[Rgn,Series])) , 0)
Units: dmnl
218) NBL3[Rgn,Series] = if then else (Di[Rgn,Series] > 0, - GAMMA LN (Di[Rgn,Series] + 1) - (Di[Rgn,Series] + 1 / alp[Rgn,Series]) * ln (1 + alp[Rgn,Series] * Mu[Rgn,Series]) + Di[Rgn,Series] * (ln (alp[Rgn,Series]) + ln (Mu[Rgn,Series])) , 0) Units: dmnl
219) NBLLFlow[Rgn,Series] = (NBL1[Rgn,Series] + NBL2[Rgn,Series]) * FlowToInclude[Series] * DataIncluded[Rgn] Units: dmnl
220) Negative Test Results[Rgn] = Testing on Living[Rgn] - Positive Tests of Infected[Rgn]
Units: Person/Day
221) New Cases[Rgn] = Infection Rate[Rgn] Units: Person/Day
222) New Testing Time = 250 Units: Day
223) Nominal Hospital Capacity[Rgn] = INITIAL(Initial Population[Rgn] * Beds per Thousand Population[Rgn] / 1000) Units: Person
224) Normalized Hospital density[Rgn] = INITIAL(Bed per Square Kilometer[Rgn] / Reference Hospital Density) Units: dmnl
225) Not too few susceptibles = sum (if then else (SuscFrac[Rgn!] < MinSuscTresh , 1, 0))
Units: dmnl

226) Obesity Impact on Fatality[Rgn] = INITIAL((Obesity Rates[Rgn] / MeanObesity) ^ Sens Obesity Impact Net[Rgn]) Units: dmnl
227) Obesity Rates[Rgn] = GET VDF CONSTANTS(Constant Data File , 'DataConstants[Rgn]', 16) Units: dmnl
228) Onset of Symptoms[Rgn] = DELAY N (Infection Rate[Rgn] , Incubation Period ,0, Delay Order) Units: Person/Day
229) Onset to Detection Delay = 5 Units: Day
230) Overall Death Fraction[Rgn] = ZIDZ (Death Rate[Rgn] , All Recovery[Rgn]) Units: dmnl
231) Patient Zero Arrival[Rgn] = if then else (Time < Patient Zero Arrival Time[Rgn] :AND: Time + TIME STEP >= Patient Zero Arrival Time[Rgn] , PatientZero / TIME STEP , 0) Units: Person/Day
232) Patient Zero Arrival Time[Rgn] = 1 Units: Day
233) PatientZero = 1 Units: Person
234) payoff = 0 Units: dmnl
235) pdim : tstP,dfcP,dgtP,scuP
236) Perceived Hazard of Infection[Rgn] = (Weight on Reported Probability of Infection[Rgn] * Reported Hazard of Infection[Rgn] + (1 - Weight on Reported Probability of Infection[Rgn]) * Hazard of Symptomatic Infection[Rgn]) Units: 1/Day
237) Perceived Risk of Life Loss[Rgn] = INTEG((Indicated Risk of Life Loss[Rgn] - Perceived Risk of Life Loss[Rgn]) / if then else (Indicated Risk of Life Loss[Rgn] > Perceived Risk of Life Loss[Rgn] , Time to Upgrade Risk[Rgn] , Time to Downgrade Risk Net[Rgn]) , 0) Units: dmnl
238) PG1 : PG
239) PMAS Confirmed for Hospital Demand[Rgn] = (1 - Reference COVID Hospitalization Fraction Confirmed[Rgn]) ^ (1 / Average Acuity of Positively Tested[Rgn]) Units: dmnl
240) PMAS Unconfirmed for Hospital Demand[Rgn] = PMAS Confirmed for Hospital Demand[Rgn] + (1 - PMAS Confirmed for Hospital Demand[Rgn]) * Untested PMAS Gap with Tested[Rgn] Units: dmnl
241) "Poisson Not-tested Asymptomatic"[Rgn] = Infectious not Tested or in Hospitals Poisson[Rgn] * exp (- Average Acuity Not Hospitalized Poisson[Rgn,Notest]) Units: Person
242) Poisson Subset Not Tested Passing Gate[Rgn] = Poisson Subset Reaching Test Gate[Rgn] - Positive Tests of Infected[Rgn] Units: Person/Day
243) Poisson Subset Reaching Test Gate[Rgn] = Reaching Testing Gate[Rgn] / (1 + Additional Asymptomatic Relative to Symptomatic[Rgn]) Units: Person/Day
244) Policy Test Rate[Rgn] = if then else (Time < New Testing Time , Current Test Rate per Capita[Rgn] , Final Test Rate Per Capita[Rgn]) Units: 1/Day
245) Population[Rgn] = Infected pre Detection[Rgn] + "Infected Unconfirmed Post-Detection"[Rgn] + Susceptible[Rgn] + Recovered Unconfirmed[Rgn] + Confirmed Recovered[Rgn] + Infectious Confirmed Not Hospitalized[Rgn] + "Pre-Symptomatic Infected"[Rgn] + sum (Hospitalized Infectious[Rgn,TstSts!]) + sum (Cumulative Recovered at Hospitals[Rgn,TstSts!]) Units: Person

246) Positive Candidates Interested in Testing Poisson Subset[Rgn] = Poisson Subset Reaching Test Gate[Rgn] * Fraction Seeking Test[Rgn] Units: Person/Day
247) Positive Candidates Interested in Testing Poisson Subset Adj[Rgn] = Max (0.001 * Potential Test Demand from Susceptible Population[Rgn] , Positive Candidates Interested in Testing Poisson Subset[Rgn]) Units: Person/Day
248) Positive Testing of Infected Untreated[Rgn] = Positive Tests of Infected[Rgn] * Fraction Poisson not Hospitalized[Rgn,Tested] Units: Person/Day
249) Positive Tests of Infected[Rgn] = Positive Candidates Interested in Testing Poisson Subset[Rgn] * (1 - Fraction Interseted not Correctly Tested[Rgn]) Units: Person/Day
250) Post Mortem Test Delay = 1 Units: Day
251) Post Mortem Test Rate[Rgn] = Post Mortem Tests Total[Rgn] * Sensitivity of COVID Test Units: Person/Day
252) Post Mortem Test Untreated[Rgn] = Post Mortem Test Rate[Rgn] * Frac Post Mortem from Untreated[Rgn] Units: Person/Day
253) Post Mortem Testing Need[Rgn] = SMOOTHI ((Deaths of Symptomatic Untested[Rgn] + Hospitalized Infectious Deaths[Rgn,Notest]) * Fraction of Fatalities Screened Post Mortem[Rgn] , Post Mortem Test Delay , 0) Units: Person/Day
254) Post Mortem Tests Total[Rgn] = min (Post Mortem Testing Need[Rgn] , Active Test Rate[Rgn]) Units: Person/Day
255) "Post-Detection Phase Resolution Time" = 10 Units: Day
256) PostMortemCorrection[Rgn] = min (Hospitalized Infectious[Rgn,Notest] / MinAdjT , Post Mortem Test Rate[Rgn] * (1 - Frac Post Mortem from Untreated[Rgn])) Units: Person/Day
257) Potential Hospital Demand[Rgn,Notest] = Hospital Demand from Not Tested[Rgn]
258) Potential Hospital Demand[Rgn,Tested] = Hospital Demand from Tested[Rgn] Units: Person/Day
259) Potential Test Demand from Susceptible Population[Rgn] = (Susceptible[Rgn] + Recovered Unconfirmed[Rgn] + Cumulative Recovered at Hospitals[Rgn,Notest]) * (Baseline Daily Fraction Susceptible Seeking Tests[Rgn] * Fraction Seeking Test[Rgn] + Multiplier Recent Infections to Test[Rgn] / Population[Rgn] * Recent Detected Infections[Rgn]) Units: Person/Day
260) "Pre-Symptomatic Infected"[Rgn] = INTEG(Infection Rate[Rgn] + Patient Zero Arrival[Rgn] - Onset of Symptoms[Rgn] , 0) Units: Person
261) PriorEndoAve : UpAdj,DwnAdj,RFI,RfSkTs,WRpPIn,MInfTs,MnCnFrc,SnCnRdUt,CfImCn,ImPDnHs,ImTrFt,DrdFac,MxHsFr,BsFtRt,SnsWth,Acty,SnFtAc,TtAsyFr,ObsImp,ChrImp,LivImp,MTrAsym
262) PriorErrs[Rgn,Priors] = INITIAL(ZIDZ (ActiveAve[Priors] - RegionalInputs[Priors,Rgn] , AbsStd[Priors]) ^ 2 / 2)
263) PriorGen : BsFtRt,SnsWth,Acty,SnFtAc,TtAsyFr,ObsImp,ChrImp,LivImp,MTrAsym
264) Priors : UpAdj,DwnAdj,RFI,PMT,RfSkTs,WRpPIn,MInfTs,MnCnFrc,SnCnRdUt,CfImCn,ImPDnHs,ImTrFt,DrdFac,MxHsFr,BsFtRt,SnsWth,Acty,SnFtAc,TtAsyFr,ObsImp,ChrImp,LivImp,MTrAsym

265) Prob Missing Symptom[Rgn] = Max (0, ln (Y[Rgn]) / Flu Acuity + 1) Units: dmnl
266) Probability of Missing Acuity Signal at Hospitals[Rgn,Tested] = ZIDZ (ln (Max (1e-06, 1 - ZIDZ (Hospital Admits All[Rgn,Tested] , Positive Tests of Infected[Rgn]))) , Average Acuity of Positively Tested[Rgn]) + 1
267) Probability of Missing Acuity Signal at Hospitals[Rgn,Notest] = ZIDZ (ln (Max (1e-06, 1 - ZIDZ (Hospital Admits All[Rgn,Notest] , Poisson Subset Not Tested Passing Gate[Rgn]))) , Average Acuity of Untested Poisson Subset[Rgn]) + 1 Units: dmnl
268) PseudoCFR Units: dmnl
269) R Effective Reproduction Rate[Rgn] = ZIDZ (Infection Rate[Rgn] , Total Weighted Infected Population[Rgn]) * Total Disease Duration Units: dmnl
270) Reaching Testing Gate[Rgn] = Infected pre Detection[Rgn] / Onset to Detection Delay Units: Person/Day
271) Realistic R0 = sum (if then else (R Effective Reproduction Rate[Rgn!] > MaxRTresh , 1, 0)) Units: dmnl
272) Recent Detected Infections[Rgn] = SMOOTHI (Positive Tests of Infected[Rgn] , Time to Respond with Tests , 0) Units: Person/Day
273) Recovered Unconfirmed[Rgn] = INTEG(Recovery of Untested[Rgn] , 0) Units: Person
274) Recovery of Confirmed[Rgn] = Tested Untreated Resolution[Rgn] * (1 - Fatality Rate Untreated[Rgn,Tested]) Units: Person/Day
275) Recovery of Untested[Rgn] = ("Infected Unconfirmed Post-Detection"[Rgn] / "Post-Detection Phase Resolution Time") - Deaths of Symptomatic Untested[Rgn] Units: Person/Day
276) Reference COVID Hospitalization Fraction Confirmed[Rgn] = 0.7 Units: dmnl
277) Reference Force of Infection[Rgn] = 0.6 Units: 1/Day
278) Reference Hospital Density = 6.06 Units: Person/(Km*Km)
279) RegionalInputs[UpAdj,Rgn] = Log (Time to Upgrade Risk[Rgn] , 10)
280) RegionalInputs[DwnAdj,Rgn] = Log (Time to Downgrade Risk[Rgn] , 10)
281) RegionalInputs[RFI,Rgn] = Reference Force of Infection[Rgn]
282) RegionalInputs[PMT,Rgn] = Sensitivity Post Mortem Testing to Capacity[Rgn]
283) RegionalInputs[RfSkTs,Rgn] = Baseline Daily Fraction Susceptible Seeking Tests[Rgn]
284) RegionalInputs[WRpPIn,Rgn] = Weight on Reported Probability of Infection[Rgn]
285) RegionalInputs[MInfTs,Rgn] = Multiplier Recent Infections to Test[Rgn]
286) RegionalInputs[MnCnFrc,Rgn] = Min Contact Fraction[Rgn]
287) RegionalInputs[SnCnRdUt,Rgn] = Sensitivity of Contact Reduction to Utility[Rgn]
288) RegionalInputs[CfImCn,Rgn] = Confirmation Impact on Contact[Rgn]
289) RegionalInputs[ImPDnHs,Rgn] = Impact of Population Density on Hospital Availability[Rgn]
290) RegionalInputs[ImTrFt,Rgn] = Impact of Treatment on Fatality Rate[Rgn]
291) RegionalInputs[DrdFac,Rgn] = Log (Dread Factor in Risk Perception[Rgn] , 10)
292) RegionalInputs[MxHsFr,Rgn] = Reference COVID Hospitalization Fraction Confirmed[Rgn]
293) RegionalInputs[BsFtRt,Rgn] = Base Fatality Rate for Unit Acuity Net[Rgn]
294) RegionalInputs[SnsWth,Rgn] = Sensitivity to Weather Net[Rgn]

295) RegionalInputs[Acty,Rgn] = Covid Acuity Relative to Flu Net[Rgn]
296) RegionalInputs[SnFtAc,Rgn] = Sensitivity of Fatality Rate to Acuity Net[Rgn]
297) RegionalInputs[TtAsyFr,Rgn] = Total Asymptomatic Fraction Net[Rgn]
298) RegionalInputs[ObsImp,Rgn] = Sens Obesity Impact Net[Rgn]
299) RegionalInputs[ChrImp,Rgn] = Sens Chronic Impact Net[Rgn]
300) RegionalInputs[LivImp,Rgn] = Sens Liver Impact Net[Rgn]
301) RegionalInputs[MTrAsym,Rgn] = Multiplier Transmission Risk for Asymptomatic Net[Rgn]
302) Relative Risk of Transmission by Hospitalized = 1 Units: dmnl
303) Relative Risk of Transmission by Presymptomatic = 1 Units: dmnl
304) Reported Hazard of Infection[Rgn] = Positive Tests of Infected[Rgn] / Susceptible[Rgn] Units: 1/Day
305) Response Policy Time On = 1000 Units: Day
306) Response Policy Weight[pdim] = 0 Units: dmnl
307) Rgn : Albania,Argentina,Armenia,Australia,Austria,Azerbaijan,Bahrain,Bangladesh,Belarus,Belgium,Bolivia,Bosnia,Bulgaria,Canada,Chile,Colombia,CostaRica,Croatia,Cuba,CzechRepublic,Denmark,Ecuador,ElSalvador,Estonia,Ethiopia,Finland,France,Germany,Ghana,Greece,Hungary,Iceland,India,Indonesia,Iran,Ireland,Israel,Italy,Japan,Kazakhstan,Kenya,Kuwait,Kyrgyzstan,Latvia,Lithuania,Luxembourg,Malaysia,Maldives,Mexico,Morocco,Nepal,Netherlands,NewZealand,Nigeria,NorthMacedonia,Norway,Pakistan,Panama,Paraguay,Peru,Philippines
308) ,Poland,Portugal,Qatar,Romania,Russia,SaudiArabia,Senegal,Serbia,Singapore,Slovakia,Slovenia,SouthAfrica,SouthKorea,Spain,Sweden,Switzerland,Thailand,Tunisia,Turkey,UAE,UK,Ukraine,USA
309) Rgn1 : Rgn
310) SAVEPER = 1 Units: Day
311) Sens Chronic Impact = 1e-06 Units: dmnl
312) Sens Chronic Impact Net[Rgn] = INITIAL(Sens Chronic Impact * (1 - SW Gen[ChrImp]) + SW Gen[ChrImp] * InputAve[ChrImp]) Units: dmnl
313) Sens Liver Impact = 1e-06 Units: dmnl
314) Sens Liver Impact Net[Rgn] = INITIAL(Sens Liver Impact * (1 - SW Gen[LivImp]) + SW Gen[LivImp] * InputAve[LivImp]) Units: dmnl
315) Sens Obesity Impact = 1e-06 Units: dmnl
316) Sens Obesity Impact Net[Rgn] = INITIAL(Sens Obesity Impact * (1 - SW Gen[ObsImp]) + SW Gen[ObsImp] * InputAve[ObsImp]) Units: dmnl
317) SensCovidUntestedAdmission = 1 Units: dmnl
318) Sensitivity of Contact Reduction to Utility[Rgn] = 15 Units: dmnl
319) Sensitivity of Contact Reduction to Utility Net[Rgn] = if then else (Response Policy Time On < Time , Sensitivity of Contact Reduction to Utility Policy * Response Policy Weight[scuP] + (1 - Response Policy Weight[scuP]) * Sensitivity of Contact Reduction to Utility[Rgn] , Sensitivity of Contact Reduction to Utility[Rgn]) Units: dmnl
320) Sensitivity of Contact Reduction to Utility Policy = 10 Units: dmnl
321) Sensitivity of COVID Test = 0.7 Units: dmnl
322) Sensitivity of Fatality Rate to Acuity[Rgn] = 2 Units: dmnl

323) Sensitivity of Fatality Rate to Acuity Net[Rgn] = INITIAL(Sensitivity of Fatality Rate to Acuity[Rgn] * (1 - SW Gen[SnFtAc]) + SW Gen[SnFtAc] * InputAve[SnFtAc]) Units: dmnl
324) Sensitivity Post Mortem Testing to Capacity[Rgn] = 1 Units: dmnl
325) Sensitivity to Weather = 0.76 Units: dmnl
326) Sensitivity to Weather Net[Rgn] = INITIAL(Sensitivity to Weather * (1 - SW Gen[SnsWth]) + SW Gen[SnsWth] * InputAve[SnsWth]) Units: dmnl
327) Series : Infection,Death,Test
328) SeriesErrorTerm[Rgn,Series] = if then else (DataCmltOverTime[Rgn,Series] = :NA:, 0, (abs (DataCmltOverTime[Rgn,Series] - SimCmltOverTime[Rgn,Series])) ^ CmltErrPW) / (BaseError + DataCmltOverTime[Rgn,Series]) * CmltPenaltyScl * CmltToInclude[Series] * DataIncluded[Rgn] Units: dmnl
329) Sim Pseudo Case Fatality[Rgn] = ZIDZ (Cumulative Deaths of Confirmed[Rgn] , Cumulative Confirmed Cases[Rgn]) Units: dmnl
330) SimCmltOverTime[Rgn,Infection] = Cumulative Confirmed Cases[Rgn]
331) SimCmltOverTime[Rgn,Death] = Cumulative Deaths of Confirmed[Rgn]
332) SimCmltOverTime[Rgn,Test] = Cumulative Tests Conducted[Rgn] Units: Person
333) SimFlowOverTime[Rgn,Infection] = Post Mortem Test Rate[Rgn] + Positive Tests of Infected[Rgn]
334) SimFlowOverTime[Rgn,Death] = Post Mortem Test Rate[Rgn] + Deaths of Confirmed[Rgn] + Hospitalized Infectious Deaths[Rgn,Tested]
335) SimFlowOverTime[Rgn,Test] = Total Simulated Tests[Rgn] Units: Person/Day
336) SimTestRate[Rgn] = Total Simulated Tests[Rgn] Units: Person/Day
337) SqrdErr[Rgn,Series] = if then else (FlowResiduals[Rgn,Series] = :NA:, :NA:, FlowResiduals[Rgn,Series] ^ 2) Units: Person*Person/(Day*Day)
338) Susceptible[Rgn] = INTEG(- Infection Rate[Rgn] , Initial Population[Rgn]) Units: Person
339) SuscFrac[Rgn] = Susceptible[Rgn] / Population[Rgn] Units: dmnl
340) SW EndoAve = INITIAL(if then else (ELMCOUNT(Rgn) > 1, 1, 0)) Units: dmnl
341) SW Gen[PriorGen] = 0 Units: dmnl
342) Switch for Government Response[Rgn] = if then else (Time > Government Response Start Time[Rgn] , 1, 0) Units: dmnl
343) Symptomatic Fraction in Poisson[Rgn] = INITIAL(1 - exp (- Covid Acuity[Rgn])) Units: dmnl
344) Symptomatic Fraction Negative[Rgn] = INITIAL(1 - exp (- Flu Acuity)) Units: dmnl
345) Symptomatic Infected to Testing[Rgn] = Positive Testing of Infected Untreated[Rgn] + Hospital Admission Infectious[Rgn,Tested] Units: Person/Day
346) t3[Rgn] = (-9 * b[Rgn] + 1.7321 * Sqrt (4 * a[Rgn] ^ 3 + 27 * b[Rgn] ^ 2)) ^ (1 / 3) Units: dmnl
347) talp = 5 Units: dmnl
348) Tested Untreated Resolution[Rgn] = Infectious Confirmed Not Hospitalized[Rgn] / "Post-Detection Phase Resolution Time" Units: Person/Day

349) TestErrorFrac = 0.0001 Units: dmnl
350) TestFlowErr[Rgn] = ((DataFlowOverTime[Rgn,Test] - SimFlowOverTime[Rgn,Test]) * WTestFlowErr[Rgn]) ^ 2 Units: dmnl
351) Testing Capacity Net of Post Mortem Tests[Rgn] = Active Test Rate[Rgn] - Post Mortem Tests Total[Rgn] Units: Person/Day
352) Testing Demand[Rgn] = Positive Candidates Interested in Testing Poisson Subset[Rgn] * Symptomatic Fraction in Poisson[Rgn] + Potential Test Demand from Susceptible Population[Rgn] * Symptomatic Fraction Negative[Rgn] Units: Person/Day
353) Testing on Living[Rgn] = min (Testing Capacity Net of Post Mortem Tests[Rgn] , Testing Demand[Rgn]) Units: Person/Day
354) Tests on Negative Patients[Rgn] = Testing on Living[Rgn] * ZIDZ (Indicated fraction negative demand tested[Rgn] * Potential Test Demand from Susceptible Population[Rgn] , Indicated fraction negative demand tested[Rgn] * Potential Test Demand from Susceptible Population[Rgn] + Indicated fraction positive demand tested[Rgn] * Positive Candidates Interested in Testing Poisson Subset[Rgn]) Units: Person/Day
355) Tests Per Million[Rgn] = Cumulative Tests Data[Rgn] / Initial Population[Rgn] * 1e+06 Units: dmnl
356) ThrsInc[Rgn] = Max (FracThresh * MaxData[Rgn] , 50) Units: Person
357) TIME STEP = 0.25 Units: Day
358) Time to Adjust Testing = 30 Units: Day
359) Time to Downgrade Risk[Rgn] = 60 Units: Day
360) Time to Downgrade Risk Net[Rgn] = if then else (Response Policy Time On < Time , Time to Downgrade Risk Policy * Response Policy Weight[dgtP] + (1 - Response Policy Weight[dgtP]) * Time to Downgrade Risk[Rgn] , Time to Downgrade Risk[Rgn]) Units: Day
361) Time to Downgrade Risk Policy = 300 Units: Day
362) Time to Herd Immunity[Rgn] = XIDZ (Herd Immunity Fraction * Susceptible[Rgn] , Total Weighted Infected Population[Rgn] / Total Disease Duration , 0) Units: Day
363) Time to Respond with Tests = 5 Units: Day
364) Time to Upgrade Risk[Rgn] = 10 Units: Day
365) Total Asymptomatic Fraction[Rgn] = 0.5 Units: dmnl
366) Total Asymptomatic Fraction Net[Rgn] = INITIAL(Total Asymptomatic Fraction[Rgn] * (1 - SW Gen[TtAsyFr]) + SW Gen[TtAsyFr] * InputAve[TtAsyFr]) Units: dmnl
367) Total Covid Hospitalized[Rgn] = sum (Hospitalized Infectious[Rgn,TstSts!]) Units: Person
368) Total Disease Duration = Onset to Detection Delay + "Post-Detection Phase Resolution Time" + Incubation Period Units: Day
369) Total Simulated Tests[Rgn] = Post Mortem Tests Total[Rgn] + Testing on Living[Rgn] Units: Person/Day
370) Total Test on Covid Patients[Rgn] = Max (0, min (Positive Candidates Interested in Testing Poisson Subset[Rgn] , Testing on Living[Rgn] - Tests on Negative Patients[Rgn])) Units: Person/Day
371) Total to Official Cases Simulated[Rgn] = ZIDZ (Cumulative Cases[Rgn] , SimCmltOverTime[Rgn,Infection]) Units: dmnl

372) Total Weighted Infected Population[Rgn] = Infected pre Detection[Rgn] + "Pre-Symptomatic Infected"[Rgn] + Weighted Infected Post Detection Gate[Rgn] Units: Person
373) Transmission Multiplier for Confirmed[Rgn] = INITIAL(Baseline Transmission Multiplier for Untested Symptomatic * Confirmation Impact on Contact[Rgn]) Units: dmnl
374) Transmission Multiplier for Hospitalized[Rgn,TstSts] = INITIAL(Baseline Transmission Multiplier for Untested Symptomatic * Relative Risk of Transmission by Hospitalized * if then else (TstSts = 1, Confirmation Impact on Contact[Rgn] , 1)) Units: dmnl
375) Transmission Multiplier Pre Detection[Rgn] = INITIAL(Baseline Transmission Multiplier for Untested Symptomatic * (1 - Total Asymptomatic Fraction Net[Rgn]) + Total Asymptomatic Fraction Net[Rgn] * Baseline Risk of Transmission by Asymptomatic[Rgn]) Units: dmnl
376) Transmission Multiplier Presymptomatic[Rgn] = INITIAL((Baseline Transmission Multiplier for Untested Symptomatic * Relative Risk of Transmission by Presymptomatic) * (1 - Total Asymptomatic Fraction Net[Rgn]) + Total Asymptomatic Fraction Net[Rgn] * Baseline Risk of Transmission by Asymptomatic[Rgn] * Relative Risk of Transmission by Presymptomatic) Units: dmnl
377) TstInc[Rgn] = Active Test Rate[Rgn] Units: Person/Day
378) TstSts : Tested,Notest
379) Untested PMAS Gap with Tested[Rgn] = (1 - Allocated Fration NonCOVID Hospitalized[Rgn]) ^ SensCovidUntestedAdmission Units: dmnl
380) Untested symptomatic Infected to Hospital[Rgn] = Hospital Admission Infectious[Rgn,Notest] Units: Person/Day
381) Utility from Limited Activities[Rgn] = exp (Sensitivity of Contact Reduction to Utility Net[Rgn] * Fractional Value of Limited Activities) Units: dmnl
382) Utility from Normal Activities[Rgn] = exp (Sensitivity of Contact Reduction to Utility Net[Rgn] * (1 - Perceived Risk of Life Loss[Rgn])) Units: dmnl
383) Voluntary Reduction in Contacts[Rgn] = F[Rgn] / F0[Rgn] * (1 - Min Contact Fraction[Rgn]) + Min Contact Fraction[Rgn] Units: dmnl
384) W Ave Acuity Hospitalized[Rgn] = ZIDZ (sum (Average Acuity Hospitalized[Rgn,TstSts!] * Hospitalized Infectious[Rgn,TstSts!]) , sum (Hospitalized Infectious[Rgn,TstSts!])) Units: dmnl
385) Weather Effect on Transmission[Rgn] = CRW[Rgn] ^ Sensitivity to Weather Net[Rgn] Units: dmnl
386) Weight Max in Test Goal = 0 Units: dmnl
387) Weight on Reported Probability of Infection[Rgn] = 0.78 Units: dmnl
388) Weighted Infected Post Detection Gate[Rgn] = "Infected Unconfirmed Post-Detection"[Rgn] + Infectious Confirmed Not Hospitalized[Rgn] + sum (Hospitalized Infectious[Rgn,TstSts!]) * "Post-Detection Phase Resolution Time" / Hospitalized Resolution Time Units: Person
389) WTestFlowErr[Rgn] = if then else (DataFlowOverTime[Rgn,Test] = :NA:, 0, 1 / Max (10, DataFlowOverTime[Rgn,Test] * TestErrorFrac)) Units: Day/Person
390) Y[Rgn] = min (1, Max (1e-06, 1 - exp (- Extrapolated Estimator[Rgn]))) Units: dmnl
391) Ymix[Rgn,p2] = - b[Rgn] / (1 + a[Rgn])

392) Ymix[Rgn,p3] = (Sqrt (a[Rgn] ^ 2 - 4 * b[Rgn]) - a[Rgn]) / 2

393) Ymix[Rgn,p4] = (-0.87358 * a[Rgn]) / t3[Rgn] + 0.38157 * t3[Rgn] Units: dmnl

S9 References

1. R. Xu *et al.*, Weather Conditions and COVID-19 Transmission: Estimates and Projections. *medRxiv*, (2020).
2. Z. Du *et al.*, Serial interval of COVID-19 among publicly reported confirmed cases. *Emerging infectious diseases* **26**, 1341 (2020).
3. H. Nishiura, N. M. Linton, A. R. Akhmetzhanov, Serial interval of novel coronavirus (COVID-19) infections. *International journal of infectious diseases*, (2020).
4. H. Rahmandad, K. Hu, Modeling the rework cycle: capturing multiple defects per task. *Syst Dynam Rev* **26**, 291-315 (2010).
5. W. Wang *et al.*, Detection of SARS-CoV-2 in different types of clinical specimens. *Jama* **323**, 1843-1844 (2020).
6. Y. Fang *et al.*, Sensitivity of chest CT for COVID-19: comparison to RT-PCR. *Radiology*, 200432 (2020).
7. R. Verity *et al.*, Estimates of the severity of coronavirus disease 2019: a model-based analysis. *The Lancet infectious diseases*, (2020).
8. WHO. (2020).
9. Z. Wu, J. M. McGoogan, Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. *Jama* **323**, 1239-1242 (2020).
10. W. Bank. (2020).
11. J. A. Vrugt *et al.*, Accelerating Markov chain Monte Carlo simulation by differential evolution with self-adaptive randomized subspace sampling. *International Journal of Nonlinear Sciences and Numerical Simulation* **10**, 273-290 (2009).
12. E. Dong, H. Du, L. Gardner, An interactive web-based dashboard to track COVID-19 in real time. *The Lancet Infectious Diseases*.
13. M. Roser, H. Ritchie, E. Ortiz-Ospina, J. Hasell, in *Our World in Data*. (2020).
14. Z. Lipton, J. Ellignton, K. Riely. (The Atlantic).